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Abstract
Problem Statement: Heart failure (HF) is a complex cardiovascular disease that affects 6.2
million Americans and is associated with high morbidity and mortality, with almost 400,000
deaths annually. Medication adherence in HF can lower the risk of death and rehospitalization.
As many as 46% of heart failure patients have medication nonadherence. The 2021 Update to the
2017 American College of Cardiology Expert Consensus Decision Pathway for Optimization of
Heart Failure Guidelines recommends smartphones or other mobile health (mHealth)
applications (apps) for medication adherence tracking.
Purpose: This evidence-based practice project aimed to assess the readiness of HF
patients admitted to an inner-city HF unit to use mHealth technology, particularly the Medisafe
medication management app after discharge, to enhance medication adherence. After verbal
consent, these participants answered survey questions on current technology use patterns,
mHealth app use and future interest, and self-reported medication adherence.
Methods: After stabilization, participants were recruited during Standardized
Interdisciplinary Bedside Rounds (SIBR) in the specialty HF acute care setting. The student
researcher used an electronic tablet to read the survey questions to the consenting participant,
and all data was recorded and maintained through REDCap.
Inclusion Criteria: All English-speaking HF patients aged 18 and above admitted to the
acute HF unit without COVID-19, dementia, or illegal substance abuse and not incarcerated.
Analysis: Descriptive and analytic statistics were used with Excel and Intellectus to
evaluate survey responses for app use readiness, demographics, and response findings.
Implications for Practice: Provide data on the readiness of patients to utilize a
smartphone app to monitor medication adherence after discharge from this large health system.
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Assessing the Readiness of CHF Patients to Use the Medisafe App to Increase Medication
Adherence
Heart Failure (HF) is a complex disease described by Choi et al. (2019) as occurring with
increasing prevalence and a high mortality rate that is associated with the complication of
hospitalization and association with previous heart disease from myocardial infarction, valvular
heart disease, and various types of cardiomyopathies. It requires treatment with pharmacologic
and non-pharmacologic therapies. Ponikowski et al. (2016) and The Task Force for the
Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of
Cardiology (ESC) defined HF as a clinical syndrome with symptoms of breathlessness, ankle
swelling, and fatigue that may have the accompanying clinical signs of increased jugular venous
pressure, and pulmonary and peripheral edema. HF can have a reduced or preserved cardiac
output with or without increased intracardiac pressures at rest or exercise. Medication adherence
is a self-care strategy for symptom management, preservation of physical functioning, and
prevention of disease progression in those with HF. A meta-analysis of 48 studies showed a
10.6% lower mortality risk in HF patients who received medication adherence interventions and
a decreased risk of rehospitalization (Ruppar et al., 2016).
Background
The Centers for Disease Control and Prevention (CDC, 2021a) states approximately 6.2
million Americans have HF, and 379,800 death certificates in 2017 in the US mentioned HF. The
CDC reported a national HF cost in 2012 estimated at $30.7 billion, including the cost of health
care services, HF medications, and missed workdays. Heart failure was listed as the fifth most
expensive condition treated in US hospitals in 2017 and represented three percent of all hospital
costs, amounting to $13,583,000,000 and 1,091,000 hospital stays (Liang et al., 2020). Heart
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failure is among the top five most costly diagnoses for all four payer groups, including Medicare,
Medicaid, private insurance, and self-pay. It was the third most expensive diagnosis for Medicare
in 2017, accounting for the highest cost of circulatory diseases (Liang et al., 2020). From 2015 to
2017, among Medicare beneficiaries, the CDC (2021b) reported 16.4 hospitalizations per 1,000
persons in the US and 16.2 hospitalizations per 1,000 persons in South Carolina. Discharges to
home in the same period were 64.6% nationally and 64.8% in South Carolina. The HF death rate
nationally for 2015-2017 was 174.7 per 100,000 persons in the US and 214.2 per 100,000
persons in South Carolina (CDC, 2021b).
Treatment of HF begins right after identifying the diagnosis and is based on the class or
strength of the recommendation. Heart failure is a multi-faceted disease. Of those patients
admitted for HF, only 20% are due to new-onset HF (Givertz & Colucci, 2013). Inpatient
pharmacologic therapy includes loop diuretics to reduce fluid volume overload, intravenous
vasodilators, and potentially intravenous positive inotropes (Sinnenberg & Givertz, 2020). The
outpatient pharmacologic treatment utilizes the continuation of diuretics in oral form, plus betablockers with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with or
without neprilysin inhibition, mineralocorticoid receptor antagonists, hydralazine, and nitrates
(Metz & Felker, 2019). Newer medication therapies may also include Ivabradine, an I f channel
blocking agent for heart rate control, and novel hypoglycemic agents such as sodium-glucose
cotransporter -2 inhibitors (Fedson et al., 2019). Many patients may be on eight or more
prescribed medications, requiring close monitoring for desirable therapeutic and adverse effects.
Clinical judgment is essential when developing the medication treatment plan, but it is equally
important to consider the patient's quality of life and personal interests (Yancy et al., 2017).
Ponikowski et al. (2016) and The Task Force for the Diagnosis and Treatment of Acute and

MEDICATION APP USE READINESS IN CHF PATIENTS

5

Chronic Heart Failure of the European Society of Cardiology (ESC) described the requirement of
providers to apply all evidence-based advances in medication regimes for HF treatment.
Wu & Moser (2018), in a secondary data analysis of two prospective studies on
medication adherence in 219 HF patients, found that 46% of patients with HF symptoms had
medication nonadherence. Those with heart failure symptoms carried a higher risk of a future
cardiac event and death. Wu & Moser (2018) recommended developing effective interventions to
improve adherence to medication for better outcomes and survival of HF patients. Studies aimed
at the prevention of major adverse cardiac events (MACE) and cardiovascular disease prevention
through medication app use found statistical significance in MACE reduction, increased
adherence to dual antiplatelet therapy, and improved overall medication adherence with using
medication management apps (Johnston et al., 2016; Liu et al., 2019; Park et al., 2020; Santo et
al., 2019). Park et al. (2020) found patients highly rated the Medisafe app (2022). The 2021
Update to the 2017 American College of Cardiology Expert Consensus Decision Pathway for
Optimization of Heart Failure (Maddox et al., 2021) addresses the identified ten pivotal issues
related to managing HF with reduced ejection fraction, including recommendations for enhanced
use of medication adherence interventions. The guidelines recommend using real-time tools that
support medication adherence, including smartphones or other mobile health (mHealth)
applications (apps) that provide an interactive platform for patient education, medication
reminders, warnings, and adherence tracking.
Problem Statement
The ESC Task Force reported that HF patients benefit from regular outpatient follow-up,
monitoring for complications or disease progression, and ensuring optimal dosing of medicines.
Activities required by the care team include ensuring patients understand the indications, dosing,
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and side effects of drugs. Patients need to recognize common disease complications, know when
to contact a healthcare professional, and recognize the necessity and benefit of taking the
medications as prescribed. The healthcare professional is responsible for providing at least
written and oral information on prescribed medicines' uses, dosages, and side effects, but more
comprehensive intervention is needed (Ponikowski et al., 2016).
Prisma Health (n.d.) Richland Heart Hospital maintains Joint Commission and the
American Heart Association Advanced Certification in HF management. Medicare Compare
(2021) lists a 12% death rate at this facility for HF patients, equal to the national HF death rate.
Medicare pays an average of $19,159 for HF patients admitted to Prisma Health Richland. The
HF 30-day readmission rate for Prisma Health Richland in 2020 was 16.83%. Urbich et al.
(2020) reviewed eighty-seven studies detailing the cost of heart failure in the U.S. between
January 2014 and March 2020, finding the annual median total medical expenses for HF care
estimated at $24,383 per patient $15,879 of that resulted from hospitalization.
Based on the interest in using novel interventions for increasing medication knowledge
and adherence to reduce morbidity, mortality, and costs in heart failure patients, the appropriate
PICOT question is: In heart failure patients admitted during an acute care admission (P), can
surveying patients on technology and mHealth app use, interests, and readiness (I) compared to
standard discharge medication management practice (C) establish feasibility for implementing
the post-discharge use of the Medisafe medication management app (O) over the 30 day survey
period (T)? This evidence-based practice project aimed to determine the impact of a survey on
the interest in and feasibility of using the Medisafe app for medication adherence in HF patients
in a large health system.
Review of the Literature
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The student researcher used PubMed-Medline, CINAHL, EMBASE, and the Cochrane
Library databases and performed fifteen separate searches from September 2020 to the present.
The student researcher used search concepts from the PICOT question resulting in 325 articles to
evaluate the content further. Through personal critical evaluation of these 325 articles, the
student researcher chose fifteen clinically relevant manuscripts supporting the use of the
Medisafe app for medication adherence which is available in further detail in the Evidence Table
in Appendix A.
The review of the literature provided supporting evidence for using the Medisafe app to
improve medication adherence. Researchers endorse the use of the Medisafe app, given the app's
ability to provide medication reminders, appointment reminders, advanced medication dosage
scheduling, and prescription renewal through the app to ensure medication coverage to avoid
missed days (Park et al., 2020; Santo et al., 2019). The app allows the user to assign a person to
share the medication-taking information recorded in the app and connect with health care
providers. The Medisafe app maintains the user’s medication administration or adherence
records, enables users to record reasons for missed medications, and allows for downloading an
Excel spreadsheet in real-time to share with others to validate medication-taking habits. The use
of an app can improve medication adherence (Al-Arkee et al., 2021; Armitage et al., 2020;
Athilingham et al., 2017; Coorey et al., 2018; Gong et al., 2020; Johnston et al., 2016; Liu et al.,
2019; Mohammadi Torkabad et al., 2020; Park et al., 2020; Santo et al., 2019; Wei et al., 2021).
Some researchers find medication adherence self-reporting somewhat limiting and
reported that patients might overestimate actual adherence levels (Kronish and Ye, 2013; Voils et
al., 2011). The Morisky Medication Adherence Scale (MMAS), in some form, was used to
identify those persons for whom medication self-reported adherence is a problem, and the use of
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a medication reminder and management app may be helpful (Athilingam et al., 2020; Gong et
al., 2020; Liu et al., 2019; Mohammadi Torkabad, 2020; Morawski et al., 2018; Patel et al.,
2013; Santo et al., 2019). The MMAS scales are valid and reliable tools for patient self-reporting
medication adherence from forgetfulness, carelessness, stopping the drug when feeling better, or
starting the drug when feeling worse (Morisky et al., 1986; Morisky et al., 2008).
The Voils DOSE-Nonadherence Measure (Voils et al., 2012) is another self-reporting
medication adherence measure with high internal validity. The initial use of the Voils DOSENonadherence Measure was to examine the extent of self-reported medication adherence in
patients with hypertension. It correlated well with improvements in systolic and diastolic blood
pressure measurement and electronic medication adherence measurement (Voils et al., 2012).
The MMAS scales and Voils DOSE-Nonadherence measure have high internal consistency for
self-reported medication adherence assessment. However, the Voils DOSE-Nonadherence
measure is better suited to evaluate the social, situational, economic, or side effect reasoning
surrounding medication nonadherence (Morisky et al., 2008; Voils et al., 2012). Using these
tools requires permission, and the MMAS scale is costly, even to the student researcher.
Despite these available self-reporting medication adherence tools, mHealth apps are
practical, cost-free, easily accessible tools in HF for improved self-care, self-confidence, and
medication adherence and were well-liked by the study participants (Athilingam et al., 2017;
Wei et al., 2021). These apps increased knowledge and quality of life scores in HF patients. In a
survey of fifty HF patients, Sohn et al. (2019) found from their questionnaire that more than 60%
of respondents were interested in the use of a mHealth app for symptom information and
management, for HF medications and treatments, and 90% reported a desire to receive care
reminders, and 71% indicated a willingness to receive medication reminders.
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mHealth apps provide the patient with feelings of empowerment. Some app users thought
they could better engage with their general practitioner about their BP readings for better blood
pressure control (Morrissey et al., 2018). The Medisafe app, as well as medication apps from
several other countries, provided varying degrees of BP improvement, with an overall downward
trend in BP, providing clinical improvement while improving medication adherence in
randomized control trials (Gong et al., 2020; Mohammadi Torkabad et al.; 2020, Morawski et al.,
2018; Santo et al., 2019). In their seminal pilot feasibility study, Patel et al. (2013) found in a
group of high-risk predominantly African-American hypertensive patients, of which 79% were
found to be medication nonadherent at baseline, that medication adherence improved with using
the mHealth app in their study on the cell phones they provided with minor improvements in BP
measurements.
As described above, studies aimed at the prevention of major adverse cardiac events
(MACE) and cardiovascular disease prevention through medication app use found statistical
significance in MACE reduction, increased adherence to dual antiplatelet therapy, and improved
overall medication adherence with high app use ratings (Johnston et al., 2016; Liu et al., 2019;
Park et al., 2020; Santo et al., 2019). These findings occurred with Medisafe app use (Park et al.,
2020). Two randomized control trials (Liu et al., 2019; Santo et al., 2019) demonstrated
improved patient lipid levels using a smart app. One of these studies used the Medisafe app
(Santo et al., 2019), and both showed enhanced medication adherence.
Several studies reported the possibility of the Hawthorne Effect (Gong et al., 2020;
Johnston et al., 2016; Liu et al., 2019; Morawski et al., 2018; Patel et al., 2013) with study
participants having high medication adherence in the control group, knowledge of the use of the
Medisafe app despite the researchers blinding the app name, increased adherence to medication
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from baseline to before launching app use, and in particular in those in one study who received a
phone for use. Although the Hawthorne Effect suggests a bias, it also indicates the general
eagerness to use the app.
Theoretical Framework
Al-Ganmi et al. (2018), in a mixed-method study with a pilot randomized control trial,
cited the use of Bandura's social cognitive theory, mainly self-efficacy, to determine the effects
of individual, behavioral, and environmental factors on patients' medication adherence. Bandura
(2004) described Social Cognitive Theory with perceived self-efficacy, believing a person has
control over health habits and can establish health goals with firm plans and strategies to realize
those goals. Bandura believed that self-efficacy is the basis for human motivation and action.
Unless one believes that an action can be personally produced with the desired effects, there is
not much incentive to act or persevere in the face of difficulty. Bandura adds that the stronger a
person's perceived self-efficacy is, the goals and aspirations are higher, and the more firmly
committed to accomplishing them. Those with low self-efficacy are apt to surrender to despair
and feelings of futility. The ideal is to support the strategies that raise the perception of selfefficacy. The Medisafe app maintains medication adherence records, enables users to record
reasons for missed medications, and allows for downloading an Excel spreadsheet to share with
family, nurses, providers, and pharmacists to validate medication-taking habits. Real-time patient
support in the clinical setting with clinician access to review medication-taking practices and
clarify difficulties encourages the patient to demonstrate app use proficiency, potentially
increasing medication adherence and self-efficacy.
Bandura (2004) recommended technologies and systems that build motivation and selfmanagement skills that guide the habit changes. He commented on medication nonadherence as a
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severe and pervasive problem that worsens health and increases healthcare costs. He even
discussed the escalation of medication regimes in response to medication nonadherence which
can have serious consequences. Dr. Shapiro’s Medisafe research (2021) validated that Medisafe
app success occurs best when a clinician introduces the app to the patient and provides continued
clinical support with routine follow-up. App adoption rates were as high as forty-five percent
when a clinician personally introduced it. Medisafe documented an increase in medication
adherence of twelve to sixteen percent from aggregate app use data.
Balapour et al. (2019) built on Bandura's self-efficacy theory with their study on
perceived mobile technology identity (MTI). The more a person uses technology, the more
reliant they feel on it, promoting continued use and improved self-efficacy. They found that
previous information technology experience positively influenced patients' intention to use
mHealth apps to self-report their health status. The Medisafe app has behavior detection built-in
from users marking meds as being taken or not, and if not, why. It contains personalized support
content to allow interface with the healthcare team. An excel spreadsheet can be downloaded to
review medication-taking behaviors at the time of the encounter. Medisafe provides additional
personal support by emailing each user a recap of the previous week's medication-taking history
and history over time each Monday, reinforcing positive behaviors and providing
recommendations for improvement in medication-taking behaviors.
The Medisafe app, with the potential for improving self-efficacy, augmented by the
uniquely tailored inpatient and outpatient heart failure care processes at Prisma Health Richland,
affords opportunities for potentially improved medication adherence successes, resulting in
improved outcomes, quality of life, and overall care provision for this population.
Project Purpose, Objectives, Expected Outcomes
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This project's purpose was to survey those patients admitted with HF to the specialty
inpatient unit on their current use of technology and assess their readiness and interest in using
mHealth technology post-discharge, specifically the Medisafe app medication reminders,
medication information, and appointment reminders, ultimately to increase medication adherence
after an acute care admission. The aim was to determine app use feasibility to inform the
healthcare system on the patient readiness for introducing a medication management app, the
Medisafe app.
Project Design
Practice Setting
This unique HF inpatient and outpatient clinical setting in central South Carolina is a
metropolitan teaching hospital, within a large health system, with a dedicated heart hospital that
maintains an advanced HF management certification (Prisma Health, n.d.), providing the
opportunity to improve medication adherence. Ideally, patients admitted with HF go to the
specialized acute care HF unit, an inpatient unit with 20 beds. One of five dedicated
multidisciplinary HF teams led by an HF Cardiologist delivers care to monitor inpatient
medication and therapies. Patients are scheduled for outpatient follow-up in the Advanced Heart
Health Center within seven days of discharge. The heart failure 30-day readmission rate for this
tertiary care facility in 2020 was 16.83%. Most HF patients receive follow-up care at the
dedicated HF Center, serving over 8,000 patients annually (L. Brodie, personal communication,
May 23, 2021). This project occurred during the beginning of the third year of the COVID-19
pandemic. The longevity of the pandemic placed unprecedented strains on the healthcare system,
including personnel shortages, resource constraints, and system restructuring. As a result, there
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was the emphasis on assessing the interest and feasibility of admitted HF in using mHealth
applications before dedicating personnel and resources for Medisafe app implementation.
Feasibility
Prisma Health Richland's (PHR) Advanced Certification in HF Management (Prisma
Health, 2021) provided the unique opportunity for identifying patients interested in improving
medication management with mHealth after HF admission with close follow-up in the outpatient
care area. The facility has the advantage of five multidisciplinary heart failure teams for patient
management, with dedicated HF cardiologists, advanced practice providers, nurses, pharmacists,
case managers, and social workers providing continuity of care. A long-standing dedicated nurse
manager oversees both the inpatient and outpatient heart failure programs, maintaining fluency
for the transition of care and workflow in the Advanced Heart Failure Program.
The Pew Research Center (2021, October 7) provided information on smartphone use in
the U.S., with 97% of Americans owning a cell phone, and 85% of those are smartphones. Of
those 65 years and older, 92% have a cell phone, and 61% of those are smartphones. Rural,
suburban, and urban residents have a cellphone ranging from 94% in rural to 98% in urban areas.
Of those, 80% are smartphones in rural areas to 89% in urban areas. On a single day in the
inpatient and outpatient units, the student researcher and nurse manager observed every patient
had a smartphone in their possession.
Population of Interest
Demographics for those admitted with HF at PHR in 2020 demonstrated most patients
were aged 46-65 (47%), African-American (57%), males (57%), discharged to home (50%), with
an average length of stay of 7 days, and 46% have Medicare (L. Brodie, personal
communication, September 12, 2021). Participants for this project were from the convenience
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sample of those admitted to the inpatient HF specialty acute care unit with HF diagnosis. The
participants were English-speaking, 18 years old and above, those without evidence of illegal
substance addiction, COVID-19, or dementia, discharged to home or self-care and agreed to
participate with informed verbal consent. Those incarcerated were not included.
Project Type
This project was an evidence-based practice project aimed at identifying the readiness
and the feasibility of using the Medisafe app for medication management post-discharge in a
complex patient population in a care setting with a historically identified medication adherence
problem to improve patient outcomes with one of the costliest disease processes in the US (Liang
et al., 2020).
Implementation Plan/Procedures
Evidence-Based Practice Model
The 2017 Iowa Model focuses on problems or triggers central to patients and families. It
incorporates concerns for increased use of the evidenced-based practice, increased
interprofessional collaboration, and the desire to enhance patient experiences (Iowa Model
Collaborative, 2017).
Cullen et al. (2018) describe the model process with the triggering issues as a question for
inquiry, followed by a decision on whether this topic is a priority designed for stakeholder or
organizational buy-in. If it is, the next step is to form a team. This interdisciplinary team
appraises and assembles evidence from available literature, focusing on the evidence's weight,
quality, and consistency. The team moves to pilot design with substantial evidence focusing on
patient engagement, available resources, developing implementation protocols, and outcome
evaluation plans. They collect baseline data, educate clinicians, provide materials, then collect
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and report post-pilot information (Cullen et al., 2018). The final decision point concerns whether
large-scale organizational change is appropriate. If the team deems organizational application
appropriate, they move to integrate and sustain the practice, culminating in result dissemination
(Cullen et al., 2018).
Validity is a significant strength of the Iowa Model. The Iowa Model Collaborative
(2017) cited over 3,900 requests for use from clinicians, educators, administrators, and
researchers from all 50 states and 130 countries. The model is translated into German, Japanese
and Portuguese. The model is simple to use and is intended for the clinician at the point of care.
There is a step-by-step guide, easily accessed through the publication by Cullen et al. (2018).
Most importantly, the model is patient and family-centered, focusing on improving outcomes.
Implementation Steps
The student researcher met with key stakeholders to establish organizational awareness
and support, including the PHR Heart Hospital Cardiovascular Services Executive Director, the
Nursing Practice Manager, and the Nursing Informatics (NI) Director. The interface with
Informational Technology (IT) and NI included obtaining information for the process of
requesting future approval for using the Medisafe app from an organizational security standpoint.
Informal meetings for an overview of the problem and project concepts occurred with the HF
cardiologists, nurse practitioners, physician assistants, and inpatient and outpatient pharmacists
to clarify the project intent and goals to assist the patient population these team members serve.
During inpatient Standardized Interdisciplinary Bedside Rounds (SIBR), the student researcher
met the assistant nurse manager, inpatient staff, including nurses, the nurse case manager, and
the social worker to assess the optimal time to introduce the project and survey concept. After
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IRB approval, the student researcher actively developed team enthusiasm for this evidence-based
practice project and finalized the assessment of inpatient workflow for project implementation.
Patients admitted to the inpatient unit with heart failure undergo diuresis and guidelinedirected medical therapy evaluation. Medication determination for discharge requires thorough
clinical assessment and management and may take up to three days or more. Discharge planning
happened daily during SIBR, with the HF care team discussing the application of guidelinedirected medical therapy with the patient and family, including medications for discharge.
During SIBR, the HF team provided time for patients and families to ask questions and interface
with all team members (physician, nurse practitioner or physician assistant, pharmacist, case
manager, social worker, bedside nurse) to coordinate care needs. The survey found in Appendix
B was administered during SIBR via the electronic tablet before discharge, as this is a dedicated
daily opportunity for patient and family interaction. Data was retained and managed through
REDCap (Harris et al., 2009). Verbal consent was obtained with every patient receiving the
project information handout with the project description before consenting. After providing
verbal consent, the patient participants answered the survey questions as read by the student
researcher.
Measures, Tools, and Data Plan
Schrauben et al. (2021) performed a cross-sectional survey to assess the availability and
acceptability of mHealth technology and its use in chronic kidney disease patients. Their
questions determined the extent to which study participants used email, the internet,
smartphones, and mHealth apps. They found that 70% reported internet, email, and smartphone
use, and 35% used mHealth apps. After written permission for use, questions used by Schrauben
et al. (2019) were compiled for the survey developed for use by the student researcher to provide
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information to the large health system on the potential for introducing the Medisafe app. The
project survey is shown in Appendix B.
This DNP project survey questioned patients about medication adherence, current
technology use with either the internet or email, smartphone, and mHealth app use, the purpose
of the mHealth app, and interest in the future use of digital health technologies for medication
management. Using the Medisafe app in the clinical setting can help track medication adherence.
Users can actively utilize the app for medication reminders, marking the medication as taken or
not, and if not, why. The survey responses were evaluated for current technology use and app use
readiness for app implementation within this large health system.
The student researcher was present in the clinical settings for project implementation
Monday through Friday for continuity purposes for thirty days, and ongoing data storage and
management with REDCap occurred. The student researcher identified newly admitted patients
for project participation daily during SIBR and developed a project status report and issue log for
communicating with the project mentors (Moran et al., 2020). Once the IRB approval process
was complete, the student researcher formalized the data collection start date and procedures.
REDCap was used to monitor and document demographic variables and the responses
obtained from the patient survey. Each participant was assigned a unique ID to collect all data,
including demographics. Survey data were evaluated through descriptive and inferential statistics
in Excel and Intellectus Statistics (2021).
Timeline
The student researcher used the System Development Life Cycle (SDLC) to plan,
analyze, design, test, implement, and maintain phase monitoring (Singletary, V., & Baker, E. L.,
2019) for project management. Chittick and Persaud (2001) stated planning is the most critical
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activity, requiring detailed, systematic, and team involvement for project success. It requires
clear and accurate definitions with realistic expectations. Up to a point before implementation,
the student researcher remained focused on the planning, analysis, design, and testing of certain
aspects of the project, focusing on the decisions that affected the remaining phases while
navigating the healthcare system preapproval requirements (Walsh & Johnson, 2001). The
strength of this approach allowed for systematic process reevaluation with the student project
leader and mentors. The timeline for the student researcher began at the proposal defense and
concluded with preparing the project's final manuscript and the project defense. A timeline with
essential project tasks is in Appendix C.
Resource Requirements
Cost analysis of this evidence-based practice project included determining the cost to the
organization. The student researcher assumed all costs for the necessary project administrative
resources. There is no monetary compensation to the student researcher. A tablet was borrowed
from the University of South Carolina College of Nursing for the study duration. No HF unit
staff involvement occurred outside their regular duties performed during SIBR. REDCap use is
free. There was no cost to the patient. Should the data suggest the feasibility of using the
Medisafe app, the app is free. The organization's potential cost savings is realized in preventing
future HF admissions from medication nonadherence, amounting to $15,879 per admission
(Urbich et al., 2020). See Appendix E for the final cost analysis and calculation at the project's
end.
Protection of Human Subjects
This evidence-based practice project required Institutional Review Board (IRB) approval
at the clinical facility due to the inclusion of participants within the acute clinical setting. It was
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deemed an Exempt Project Procedure (Office of Research Compliance, n.d.) as the process
involved only a survey. As the survey was completed, there was interpersonal communication
between the student researcher and the potential project participants, and verbal consent was
obtained in the clinical setting. Participants were assigned unique identifiers through REDCap
for project reference, and all data were encrypted and entered into the password-protected
platform for privacy and confidentiality protection through REDCap. Only the research team
members have access to the data as approved by the student researcher project protocol. All
demographic and inferential project data recorded are safely stored in the unique REDCap
password-protected cloud-based services with deidentified unique identifiers. The EMR was not
accessed for this project. All subjects participating in the project were informed of the project's
intent. Special protection for vulnerable and or critically ill subjects was in place. All
participants, through verbal consent, acknowledged complete understanding of the ability to
withdraw from participation at any time. All consent was obtained verbally, and verification of
consent was maintained through participation in the survey process after receiving the written
description of the approval by the IRB. The student researcher completed the mandatory
protection of human subjects training per IRB requirement.
Results and Key Findings
Descriptive and Inferential Statistics
Frequencies and percentages were calculated for age, gender, race, education,
employment status, marital status, living situation, number of hospitalizations in the last year,
type of insurance, and number of days per week with HF symptoms for all 62 participants.
The most frequently observed categories were: age, 65-80 (n = 33, 53.23%); gender, male
(n = 35, 56.45%); race, Non-Hispanic Black (n = 45, 72.58%); level of education, High School
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Diploma or equivalency (n = 31, 50.00%); current employment status, retired (n = 30, 48.39%);
marital status, married (n = 22, 35.48%); insurance, Medicare (n = 35, 56.45%); the number of
days participants experienced HF symptoms per week, 5-7 days (n = 26, 41.94%). Full
frequencies and percentages are presented in Table 1.
Table 1
Frequency Table for Demographic Variables
Variable
Age
18-30
31-50
51-64
65-80
80
Gender
Male
Female
Race
Non-Hispanic White
Non-Hispanic Black
Education
Less than High School
High School Diploma/Equivalency
Some College
Bachelor's Degree
Employment
Retired
Disabled
Employed Full-time
Unemployed
Marital Status
Married
Widow (er)
Single
Divorced

n

%

4
10
14
33
1

6.45
16.13
22.58
53.23
1.61

35
27

56.45
43.55

17
45

27.42
72.58

7
31
20
4

11.29
50.00
32.26
6.45

30
24
6
2

48.39
38.71
9.68
3.23

22
17
14
8

35.48
27.42
22.58
12.90
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Table 1
Frequency Table for Demographic Variables
Variable
Significant Other/Long-term Partner
Living Situation
Lives with Spouse/significant other/long term partner
Extended Family
Lives Alone
Children
Friends
Assisted Living
Hospitalizations in the Last Year
More Than Three Times
Twice
Once
Three Times
None
Insurance
Medicare
Medicaid
Private
Self-pay
TriCare
Days With HF Symptoms per Week
5-7
1-2
3-4
0

n
1

%
1.61

24
14
11
9
2
2

38.71
22.58
17.74
14.52
3.23
3.23

20
17
12
8
5

32.26
27.42
19.35
12.90
8.06

35
16
8
2
1

56.45
25.81
12.90
3.23
1.61

26
15
13
8

41.94
24.19
20.97
12.90

Frequencies and percentages were calculated for participants' current internet or email
use, smartphone use, electronic tablet use, tracker or smartwatch use, and mHealth app use.
Internet or email use was reported by 69.35% of participants (n = 43), smartphone use was
reported by 90.32% (n = 56), electronic tablet use was reported by 67.74% (n = 42), 82.26% (n =
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51) did not use an activity tracker or smartwatch. Frequencies and percentages are presented
in Table 2.
Frequencies and percentages were calculated for the categories of mHealth apps used by
participants. Apps to access personal medical records (n = 18, 29.03%) were used most
frequently, followed by apps used to track exercise, activity, or weight (n = 6, 9.68%) and
monitoring blood pressure. No mHealth app use at all was reported by 66.13% (n = 41). Of the
twenty-one participants who used mHealth apps, eight used only one mHealth app, six used two
mHealth apps, five used three mHealth apps, one used five mHealth apps, and one used seven
mHealth apps. mHealth app frequencies and percentages are presented in Table 3.
Table 2
Frequency Table for Technology Use Variables
Variable
Internet or Email Use
Yes
No
Smartphone Use
Yes
No
Electronic Tablet Use
Yes
No
Tracker or Smartwatch Use
Yes
No
mHealth app Use
Yes
No

n

%

43
19

69.35
30.65

56
6

90.32
9.68

20
42

32.26
67.74

11
51

17.74
82.26

21
41

33.87
66.13
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Table 3
Frequency Table for mHealth app Use
Variable
Personal Medical Record apps
No
Yes
Nutrition or Diet Information apps
No
Yes
Health Condition apps
No
Yes
Exercise/Activity/Weight apps
No
Yes
Medication apps
No
Yes
Eating Habit apps
No
Yes
Blood Pressure apps
No
Yes
Blood Glucose apps
No
Yes
Other mHealth apps
No
Yes
No mHealth app Use
Yes
No

n

%

44
18

70.97
29.03

58
4

93.55
6.45

60
2

96.77
3.23

56
6

90.32
9.68

58
4

93.55
6.45

60
2

96.77
3.23

56
6

90.32
9.68

58
4

93.55
6.45

61
1

98.39
1.61

41
21

66.13
33.87

Most participants reported not missing taking home medications in the seven days before
hospitalization (n = 43, 69.35%). Frequencies and percentages are presented in Table 4. Themes
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of reasons reported for missing medications by participants (n = 19; 30.65%) included: feeling
too sick to take medications; waking up too late to take the medication; being in the emergency
room; running out of medications; pharmacy did not have medicines in stock; was feeling better
so stopped taking medications; forgot to take medications; had medications confused. There is a
possibility that participants in this project are over-reporting medication adherence. As
previously noted, some researchers find medication adherence self-reporting somewhat limiting
and report that patients may overestimate actual adherence levels (Kronish and Ye, 2013; Voils
et al., 2011).
Table 4
Frequency Table for Missed Medication Reporting
Variable
Missed Medications
No
Yes

n

%

43
19

69.35
30.65

Overall participant interest in medication management app use was high (n =
56, 90.32%). Frequencies and percentages were calculated for medication app interest to provide
medication reminders to track medications, for looking up medication information and videos,
for receiving appointment reminders, and for no medication app use interest. The most
frequently observed categories of medication app interest were tracking medications and
receiving reminders (n = 49, 79.03%) and looking up medication information and medication
information videos (n = 49, 79.03%). Many were interested in the app's ability to provide
upcoming appointment reminders (n = 51, 82.26%). Similarly, Sohn et al. (2019) found from
their questionnaire of 50 participants that more than 60% of respondents were interested in the
use of a mHealth app for symptom information and management, HF medications, and
treatments, and 90% reported a desire to receive care reminders, and 71% indicated a willingness
to receive medication reminders. Frequencies and percentages for the DNP project sample are
presented in Table 5.

MEDICATION APP USE READINESS IN CHF PATIENTS

25

Table 5
Frequency Table for Medication app Use Interests
Variable
To receive reminders for taking and tracking medications
Yes
No
To look up medication information or watch medication videos
Yes
No
To receive appointment reminders
Yes
No
No medication app use interest
Yes
No (those interested in app use)

n

%

49
13

79.03
20.97

49
13

79.03
20.97

51
11

82.26
17.74

6
56

9.68
90.32

Strengths
The total number of participants from thirty days of collecting survey responses was 62.
Those ineligible for participation during the thirty days included eight end-stage HF patients
discharged to hospice care, eleven others were ineligible due to illicit substance use, ten others
had dementia, three had COVID, two declined to participate, and one had significant intellectual
developmental delays and no family was at the bedside. A very high number of the sixty-two
participants (n = 56) had a smartphone at 90.32%. This result is higher than the Pew Research
Center's (2021, October 7) statistics, citing that 85% of Americans have a smartphone. Figure 1
displays the smartphone use of those participating. All age ranges had smartphone use for this
DNP project sample, reinforcing the ability of all age groups to potentially use a medication
management app for improved medication knowledge and adherence. All team members
received the student researcher well, and the HF teams were very interested in using technology
to increase medication adherence and knowledge.
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Figure 1
Bar plot of Smartphone Use by Age

Limitations
This project used a convenience sample and the statistical evaluations performed were on
nominal data, the least precise level of data measurement (Salkind & Frey, 2020). Those in the
project sample who reported medication nonadherence was 30.65% (n = 19), less than that
expected from the literature of 46% (Wu & Moser, 2018). The student researcher interpreted this
higher-than-expected self-reported medication adherence from participants as a form of the
Hawthorne Effect as the student researcher was introduced by the HF team on rounds to the
potential participants as a doctoral student, working to help the HF team and HF patients.
Project Evolution
The initial intent of the project was to introduce the Medisafe app in the inpatient area
and evaluate medication-taking habits to measure changes in medication adherence at the
outpatient follow-up post-acute heart failure admission visits. Due to the effects of the pandemic,
the student researcher determined surveying current technology use, along with app use
readiness and interest, would provide information to the organization on the feasibility of
initiating a patient-facing medication management app to meet the DNP project requirements.
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The student researcher developed the survey from the literature with written permission from
Schrauben et al. (2021), was present in the clinical setting for thirty days, and obtained
information from sixty-two participants. Formal Structured Interdisciplinary Bedside Rounding
did not occur every day. Still, the student researcher rounded with the HF team members as
available, affording the introduction of the student researcher as a team member to facilitate
survey completion. Most participants were eager to answer questions and expressed enthusiasm
to participate.
Process Measures and Outcomes
Contextual Elements and the Survey
Twenty of those surveyed had been admitted to the hospital more than three times in the
last year and took four to six and seven or more medications daily. In the literature review, a
meta-analysis of 48 studies showed a 10.6% lower mortality risk in HF patients who received
medication adherence interventions and a decreased risk of rehospitalization (Ruppar et al.,
2016). Figure 2 displays the results in a Bar Plot of medications taken and hospitalizations.
Figure 2
Bar Plot of Number of Medications Taken Daily by Hospitalizations in the Last Year
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A Chi-square Test of Independence was conducted to examine whether the number of
daily medications and hospitalizations in the last year were independent. The assumption of
adequate cell size was assessed, which requires all cells to have expected values greater than zero
and 80% of cells to have expected values of at least five (McHugh, 2013). A total of 10 cells had
expected frequencies of zero, indicating the first condition was violated. A total of 16.00% of the
cells had expected frequencies of at least five, indicating the second condition was violated.
Since the assumptions of the chi-square test were violated, Fisher's exact was used to produce
more reliable results with small sample sizes. The results of the Chi-square test were significant
based on an alpha value of .05, χ2(16) = 45.16, p < .001, suggesting that number of medications
taken daily and hospitalizations in the last year were not independent. Table 6 presents the results
of the Chi-square test.
Table 6
Number of Medications Daily and Hospitalizations Observed and Expected Frequencies
Hospitalizations in the last year
Number of meds daily More than three times None Twice Three times
4-6
7[5.48] 2[1.37] 1[4.66]
4[2.19]
7
13[10.32] 0[2.58] 12[8.77]
3[4.13]
0-2
0[1.61] 1[0.40] 1[1.37]
0[0.65]
2-4
0[1.94] 0[0.48] 3[1.65]
1[0.77]
Other
0[0.65] 2[0.16] 0[0.55]
0[0.26]
Note. Values formatted as Observed [Expected].

Once
χ2 df
p
3[3.29] 45.16 16 < .001
4[6.19]
3[0.97]
2[1.16]
0[0.39]

A Fisher's exact test was conducted to examine whether the number of medications taken
daily and hospitalizations in the last year was independent. There were the same five levels in the
number of medications taken daily: 0-2, 2-4, 4-6, 7, and Other (representing vitamins or
supplements). There were the same five levels of hospitalizations in the last year: none, once,
twice, three times, and more than three times. The results of the Fisher exact test were significant
based on an alpha value of .05, p < .001, suggesting that number of medications taken daily and

MEDICATION APP USE READINESS IN CHF PATIENTS

29

hospitalizations in the last year are related to one another. Table 7 presents Fisher's exact test
results.
Table 7
Hospitalizations in the Last Year and Medications Daily Observed and Expected Frequencies
Hospitalizations in the last year
4-6
More than three times
7[5.48]
None
2[1.37]
Twice
1[4.66]
Three times
4[2.19]
Once
3[3.29]
Note. Values formatted as Observed [Expected].

Number of meds daily
0-2
7
Other
0[1.61] 13[10.32] 0[0.65]
1[0.40]
0[2.58] 2[0.16]
1[1.37]
12[8.77] 0[0.55]
0[0.65]
3[4.13] 0[0.26]
3[0.97]
4[6.19] 0[0.39]

2-4
p
0[1.94] < .001
0[0.48]
3[1.65]
1[0.77]
2[1.16]

The most frequently observed category of days with HF symptoms was 5-7 (n =
26, 41.94%). Frequencies and percentages are presented in Table 8.
Table 8
Frequency Table for Number of Days with HF Symptoms
Variable
Days with HF symptoms
0
1-2
3-4
5-7

n

%

8
15
13
26

12.90
24.19
20.97
41.94

A Chi-square Test of Independence was conducted to examine whether the number of
medications taken daily and the number of days with HF symptoms were independent. There
were five levels in medications taken daily: 0-2, 2-4, 4-6, 7, and Other (representing vitamins or
supplements). There were four levels in days with HF symptoms: 0, 1-2, 3-4, and 5-7. The
results of the Chi-square test were not significant based on an alpha value of .05, χ2(12) =
15.26, p = .227, suggesting that number of medications daily and days with HF symptoms could
be independent of one another. Table 9 presents the results of the Chi-square test.
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Table 9
Days with HF Symptoms and Meds Taken Observed and Expected Frequencies
Days with HF symptoms
Number of meds taken daily
1-2
5-7
3-4
4-6
3[4.11]
9[7.13] 2[3.56]
0-2
3[1.21]
0[2.10] 1[1.05]
7
9[7.74] 12[13.42] 9[6.71]
Other
0[0.48]
2[0.84] 0[0.42]
2-4
0[1.45]
3[2.52] 1[1.26]
Note. Values formatted as Observed [Expected].

0
χ2 df
p
3[2.19] 15.26 12 .227
1[0.65]
2[4.13]
0[0.26]
2[0.77]

A Fisher's exact test was conducted to examine whether the number of medications daily
and days with HF symptoms was independent. There were the same five levels in the number of
medications daily and the same four levels in days with HF symptoms. The results of the Fisher
exact test were not significant based on an alpha value of .05, p = .163, suggesting that the
number of medications daily and days with HF symptoms could be independent of one another.
This implies that the observed frequencies were not significantly different than the expected
frequencies. Table 10 presents the results of the Fisher's exact test.
Table 10
Days with HF Symptoms and Meds Taken Observed and Expected Frequencies
Number of meds taken daily
1-2
4-6
3[4.11]
0-2
3[1.21]
7
9[7.74]
Other
0[0.48]
2-4
0[1.45]
Note. Values formatted as Observed [Expected].

Days with HF symptoms
5-7
3-4
9[7.13]
2[3.56]
0[2.10]
1[1.05]
12[13.42]
9[6.71]
2[0.84]
0[0.42]
3[2.52]
1[1.26]

0
3[2.19]
1[0.65]
2[4.13]
0[0.26]
2[0.77]

p
.163

Unintended Consequences
The IRB required the name of the project on the DNP project description and verbal
consent information form given to the potential participants. The handout included the Medisafe
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app name, and several participants answering the survey questions told the student researcher
their intent to download the Medisafe app. Since no further contact occurred with the
participants, no data is available for those using the app.
Staffing constraints from the effects of the pandemic led to the recommendation that the
student researcher should be the only person to perform the patient survey. As a result, staff
nurses were not involved in the research process. Several verbalized a desire to have been able to
participate, commenting on the potential value of using the Medisafe app to increase medication
adherence and knowledge, as the heart failure 30-day readmission rate for this tertiary care
facility in 2020 was 16.83% (L. Brodie, personal communication, May 23, 2021).
Discussion and Future Direction for Evidence-Based Practice
Association Between the Survey and Findings
The findings of the association between the higher number of medications prescribed and
the higher numbers of hospitalizations in the DNP project sample leads the student researcher to
conclude that more medications may play a part in hospital readmissions in this population, and
there may be over-reporting of medication adherence. Since the survey responses revealed high
interest in future mHealth app use for medication management and reminders (n = 49, 79.03%),
obtaining medication information (n = 49, 79.03%), and appointment reminders (n =
51, 82.26%), there is reason to believe that the Medisafe app use would be well received in this
population. In addition to being well-received, Dr. Shapiro (2021) with Medisafe described the
best success with the Medisafe app when clinicians introduce the app for use while the patient is
in the clinical setting. The student researcher witnessed high levels of HF team interest in
Medisafe app use. Since only 20% of HF admissions are due to new-onset or acute heart failure
(Givertz & Colucci, 2013), adding or escalating medications on acute admission to those with
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chronic HF may lead to medication regime confusion post-discharge. Through the Medisafe app
medication administration reminders, patients may experience alleviation of medication regime
confusion post-discharge, especially when the app is introduced before discharge
By the HF team clinician reviewing post-discharge medication-taking habits from the
patient’s smartphone or downloadable Excel spreadsheet at the one-week follow-up, the clinician
can reinforce the positive medication adherence behavior, adding to the patient’s sense of selfefficacy. Since 79.03% of the participants expressed interest in medication information and
videos on the Medisafe app for prescribed medications, patients and family members have
immediate access to the smartphone app to address concerns about medicines anytime. The ideal
is to support the strategies of raising the perception of self-efficacy. Bandura believed that selfefficacy is the basis for human motivation and action. Unless one believes that an action can be
personally produced with the desired effects, there is not much incentive to act or persevere in
the face of difficulty. The feedback from the Medisafe app and clinical support of the Advanced
HF team can improve patient self-efficacy and promote continued Medisafe app use, leading to
improved medication adherence.
Comparison of Results with Other Publications
Schrauben et al. (2021) performed a cross-sectional survey of 932 study participants with
chronic kidney disease to assess technology use and interest in using mHealth technologies under
the pretense that using digital and mobile health technologies improves patient and provider
communication and increases information sharing. They found that 70% reported using internet
email and smartphones, and 35% used mHealth apps. After obtaining written permission, the
student researcher assessed similar data to Schrauben et al. (2021) from the current convenience
sample of 62 participants over thirty days. Internet or email use was reported by 69.35% of
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participants (n = 43), smartphone use was reported by 90.32% (n = 56), and 33.87% used
mHealth apps, similar to the chronic kidney disease population. Sohn et al. (2019) found from
their questionnaire that more than 60% of respondents were interested in using a mHealth app for
symptom information and management of HF medications and treatments, and 71% indicated a
willingness to receive medication reminders.
Schrauben et al. (2021) found that racial or ethnic minority groups in their sample
reported higher interest in using mHealth technologies than non-ethnic minorities. In this DNP
project, a Chi-square Test of Independence was conducted to examine whether internet or email
use and race were independent. There were two levels in internet or email use: no and yes. There
were two levels in the race category: Non-Hispanic White and Non-Hispanic Black (none of the
participants identified themselves as Hispanic or Asian). The Chi-square test results were not
significant based on an alpha value of .05, χ2(1) = 2.97, p = .085, suggesting that internet or
email use and race could be independent. Table 11 presents the results of the Chi-square test of
Independence.
Table 11
Technology Use and Race Observed and Expected Frequencies
Race
Internet or email use
Non-Hispanic White
No
8[5.21]
Yes
9[11.79]
Note. Values formatted as Observed [Expected].

Non-Hispanic Black
χ2 df
p
11[13.79] 2.97 1 .085
34[31.21]

Impact of the Project
Difference Between Observed and Anticipated Outcomes
The student researcher anticipated high technology and smartphone use and a high
reported desire to use mHealth medication management technology. Overreporting of medication
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adherence by project participants was also anticipated from the findings in the review of the
literature. Additionally, bias can be concluded in the survey responses as the student researcher
was the only person to conduct the survey.
Conclusions
Sustainability and Dissemination
There is no additional interest in obtaining more app use readiness information.
Dissemination of the survey findings was shared with the HF care teams and Moultrie staff
through a PowerPoint presentation just after the student researcher’s final project defense.
Additional dissemination is planned through poster presentations and publication.
Usefulness of the Work
The data obtained from this convenience sample of HF patients after admission for acute
HF showed a high interest in using a medication management app in this population. Ninety
percent of respondents had a smartphone to accommodate the Medisafe app, which is available
on the iOS and Android platforms and is free to use. During SIBR one day, one of the HF
cardiologists asked a patient if he took his HF medications regularly, and the patient attested to
medication adherence. Through rounds, it was revealed that this young patient had a worsened
left ventricular ejection fraction and had worn a life vest for sudden cardiac death prevention
before admission. The HF cardiologist pointed out that if there were a way to verify medication
adherence, the patient would have qualified for primary sudden death prevention with an
implantable cardiac defibrillator with that admission. Had the facility had the Medisafe app in
place, medication adherence could have been validated for this patient by downloading his app
usage information from an Excel spreadsheet.
Next Steps
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The student researcher recommends the health system use the data from this
project to implement the use of the Medisafe app. The 2021 Update to the 2017 American
College of Cardiology Expert Consensus Decision Pathway for Optimization of Heart Failure
(Maddox et al., 2021) addressed the ten pivotal issues related to managing HF with reduced
ejection fraction, including recommendations for enhanced use of medication adherence
interventions. The guidelines recommend using tools that support medication adherence in realtime, including smartphones or other mobile health (mHealth) applications (apps) that provide an
interactive platform for education, reminders, warnings, and adherence tracking.
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Appendix A

Evidence Table
Brief Reference,
Type of Study,
Quality rating

Article 1: AlArkee, et al.
(2021). Mobile
apps to improve
medication
adherence in
cardiovascular
disease:
Systematic
review and metaanalysis. Journal
of Medical
Internet Research
23(5), e24190.
Evidence Level 1
Quality – Very
good

Methods

Threats to Validity/ Reliability

Study Findings

Conclusions

Design: Systematic Review and
Meta-analysis of 16 Randomized
Control Trials, 12 of the RCTs
primarily addressed medication
adherence
Sample: sample sizes ranged from
24 to 412 participants.
Framework: Meta-analysis
Analysis Plan: PRISMA guidelines
Procedure: Studies were selected if
they were randomized controlled
trials if they were published in
English, if they were for patients
with cardiovascular disease such as
atrial fibrillation, coronary heart
disease, heart failure,
hypercholesterolemia, hypertension,
myocardial infarction, and stroke,
and if the intervention included an
app to improve medication
adherence. A 2-stage process was
used to select studies for inclusion
for the review. One author screened
titles and abstracts, where
ambiguities arose from the screening
process; one of two different authors
independently assessed the titles and
abstracts for relevance. Two authors
independently reassessed the
complete text studies matching the
prespecified criteria for eligibility in
the second screening stage.
Bibliographies of selected studies
were hand searched for additional
references.

Conclusion Validity: Powerful
results and estimated magnitude
Internal Validity: High
External Validity: High
Construct Validity: High
Reliability: High
Precision: The review followed the
PRISMA guidelines and was
registered in the PROSPERO
database. Quality assessment was
conducted independently by two
authors, and a consensus was
reached. The risk of bias was guided
by the Cochrane Collaboration Tool
for Randomized Controlled Trials,
with bias broadly categorized as
selection, performance, attrition, or
other. Each bias domain was further
classified as low, high, or unclear
risk of bias. AHRQ Standards were
applied, and a summary was
generated with Review Manager
software from the Cochrane
Collaboration. 4 analyses were
performed: Meta-analysis of
intervention effects or medication
adherence at different time points of
intervention. A univariate metaregression analysis regressing the
app intervention across trials on
intervention duration was run. A
meta-analysis of intervention effect
on medication adherence across all
included trials at the final time point
of intervention duration occurred. A
series of meta-analyses of
intervention effect on BP, TChol,
LDL on 3rd month of the
intervention.

Medication adherence rates showed
statistically significant
improvements in 9 RCTs. All but
two apps delivered medication
reminders to promote medication
adherence. For the majority,
delivering medication reminders to
promote medication adherence was
their primary function. Other
adherence measures included
medication event monitoring
systems. Overall, 12 trials reported
apps to enhance medication
adherence rates. Nine demonstrated
significant improvement. In the
remaining four trials, three did not
find a significant difference. One
reported a significant difference with
only one of the four medicines being
monitored. Different trial durations
were performed, demonstrating a
significant effect in favor of the app
interventions with high statistical
heterogeneity. The authors report the
heterogeneity of the trials, apps, and
outcome measures studied made
quantitative comparisons
problematic. Differences in
adherence between the medications
included in the trial lead to
difficulties with some medications
possibly having a higher rate of
nonadherence than others because of
the adverse effects and taste of
formulations.

Medication adherence rates showed
statistically significant
improvements in 9 RCTs with the
use of medication apps. In the seven
trials evaluating app usability, all
were considered acceptable. There
was variation in the app
characteristics. A total of 10
randomized controlled trials
involved health care professionals,
mainly physicians and nurses
involvement along with the appbased interventions. The apps had
mixed functionality: 2 used
education, 7 delivered reminders,
and 7 provided reminders combined
with educational support. Overall
findings include that apps tended to
increase medication adherence, and
they have an acceptable degree of
usability. Recommendations
included future large-scale studies
focusing on identifying the essential
active components of successful
apps.
Overall, support the use of
medication apps to increase
medication adherence.
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Article 2:
Armitage, L. C.,
et al. (2020). Do
mobile device
apps designed to
support
medication
adherence
demonstrate
efficacy? A
systematic
review of
randomized
control trials with
meta-analysis.
BMJ Open 10(1),
1-9.
Evidence Level 1
Quality Excellent
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Methods

Threats to Validity/ Reliability

Study Findings

Conclusions

Design: Systematic Review and
Meta-analysis of 16 Randomized
Control Trials, 9 of the RCTs
primarily addressed medication
adherence.
Sample: 83 articles yielded 9
studies with a median sample size of
102 participants, the range of
participants was 24-412 participants.
The median follow-up period was 12
weeks, with a range of 28 days to 16
weeks.
Framework: Meta-analysis
Analysis Plan: PRISMA guidelines
Procedure: A sensitive search based
on key search terms included
adherence, nonadherence,
smartphone app, and RCTs. 2
reviewers independently screened all
citations by title and abstract. Fulltext articles for all remaining
sources were screened against the
eligibility criteria. Any discrepancies
in the screening process were settled
between the initial 2 reviewers and a
3rd reviewer. RCTs relevant to
review were those that investigated
the use of an app on a mobile device
to support medication adherence.
The inclusion criteria were as
follows:1 or more Rxd medications,
an app-based intervention group, a
comparator group with usual care or
control with no app use, and
medication adherence data for both
groups.

Conclusion Validity: High
Internal Validity: High
External Validity: High
Construct Validity: High
Reliability: High
Precision: The review followed the
PRISMA guidelines. The protocol
was registered in the PROSPERO
database. Data were extracted
independently by two reviewers
using a custom data extraction form.
Participants' baseline characteristics
were extracted, including age and
sex. Raw data on medication
adherence were extracted either
from the published articles or by
emailing the authors of the primary
studies. When two adherence
measures were reported, that which
was considered most comparable
with the outcome measures of the
other included studies was used for
meta-analysis. The included trials
were assessed for risk of bias using
the Cochrane Risk of Bias Tool.
Studies were considered to be at
unclear risk of bias for an item when
the primary article did not provide
sufficient information for the
reviewers to decide categorically
between high or low risk of bias.
High precision

Of the nine studies, 4 measured
adherence using the 8 item Morisky
Medication Adherence Scale. Metaanalysis was performed, pooling
results from the 9 eligible studies
which reported data on 988
participants, to estimate the effect of
mobile apps in improving
medication adherence. The metaanalysis results indicated that
patients who participated in
medication adherence interventions
delivered by mobile apps were more
likely to adhere to prescribed
medications, OR 2.120, 95% CI
1.635 to 2.744, than those who did
not use these interventions. A focus
meta-analysis was performed,
pooling results from the 5 studies
which reported medication
adherence according to the Morisky
Medication Adherence Scale. The
results of this also indicated that
patients using medication adherence
interventions delivered by mobile
apps reported higher adherence to
prescribed medications, OR 1.83,
95% CI 1.42 to 2.36.

A rigorous systematic review of the
literature to investigate whether
mobile apps demonstrated efficacy
and supporting medication
adherence revealed random-effects
meta-analysis of pooled results from
all nine studies indicating that
people who use medication reminder
apps are significantly more likely to
adhere to their medications than
those who do not. Six of the 9
studies included in the meta-analysis
were based on self-reported
measures of adherence, the MMAS8. All nine studies reported that their
mobile app delivered interventions
that demonstrated efficacy in
supporting medication adherence,
although in five studies did not have
a statistically significant effect, four
studied did demonstrate statistical
significance interventions. This does
not mean that there is no clinical
significance.
Supports the use of mobile apps
for medication adherence.
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Article 3:
Coorey et al.
(2018).
Effectiveness,
acceptability and
usefulness of
mobile
applications for
cardiovascular
disease selfmanagement:
Systematic
review with
meta-synthesis of
quantitative and
qualitative data.
European
Journal of
Preventive
Cardiology,
25(5), 505-521.
Evidence Level II
Quality - Good
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Methods

Threats to Validity/ Reliability

Study Findings

Conclusions

Design: Systematic Review with
Meta-synthesis of quantitative and
qualitative data
Sample: 10 studies of varying
design (both quantitative and
qualitative data were used, including
randomized, non-randomized, and
qualitative only study designs were
accepted), including 607 patients
from five countries were included.
Framework: Meta-synthesis
Analysis Plan: Eligible studies were
those with an intervention
comprising a patient-directed app
primarily delivered and used on a
smartphone or tablet device to
improve adoption and or
maintenance of at least two lifestyle
behaviors, such as medication
adherence, increased physical
activity, or smoking cessation as
well as improving treatment
adherence and disease self-care
behavior through the use of
interactive self-monitoring and
information resources
Procedure: a total of 1354 records
were screened for inclusion, and 101
full-text manuscripts were reviewed
for eligibility. All manuscripts were
in English. 10 papers representing 9
studies from 5 countries were
included. 2 studies reported different
data from the same cohort, with 1
detailing quantitative results and the
other describing qualitative
evaluation.

Conclusion Validity: Strong due to
the nature of the analysis
Internal Validity: Strong
External Validity: Strong
Construct Validity: Valid Tools
Reliability: Reliable Tools
Precision: The quality appraisal of
included studies was undertaken
using one of three instruments
depending on the study design. One
reviewer assessed each study to
ensure assessments were consistent.
Using the Cochrane Risk of Bias
Tool, the primary sources of
systematic bias in the randomized
trial were assessed: used for
selection bias, performance bias,
detection bias, attrition bias, and
reporting bias. Before and after
studies were evaluated (but not
excluded) using the nine-item
Joanna Briggs Institute Critical
Appraisal Checklist for quasiexperimental studies (nonrandomized experimental studies).
Notably, 5 of the 10 domains in this
tool concerned a comparison group,
which was absent in three of the four
included studies of this type.
Qualitative/observational studies
were assessed using the Critical
Appraisal Skills Program (CASP)
tool.

Interventions included studies
targeting hypertension, heart failure,
stroke, and cardiac rehabilitation
populations. Factors that improved
among app users were
rehospitalization rates, diseasespecific knowledge, quality of life,
psychological well-being, blood
pressure, BMI, waist circumference,
cholesterol, and exercise capacity,
improved physical activity,
medication adherence & smoking
cessation from the characteristics of
apps used.
Three studies assessed medication
adherence by different methods and
reported an overall positive impact.
In 1 of the 2 uncontrolled beforeafter studies, adherence was selfreported, and responses were
checked against national
prescription repository data. The
percentage of filled prescriptions
corresponded to at least 80% of the
prescribed doses during the study
period. In the second study, patients
reported days of medication
adherence in the last 30 days at
29.25; however, no baseline data
were reported in which to compare.
In the randomized controlled trial,
self-reported drug nonadherence at
six months using the E diary app
intervention was significantly lower
in the intervention group compared
with the control group with a P=
0.025.

From this systematic review with
meta-synthesis of quantitative and
qualitative data, multiple behaviors
and cardiovascular disease risk
factors appear modifiable in the
shorter term with the use of mobile
apps. Evidence for more prolonged
effectiveness requires more
extensive, controlled studies of
longer duration, with emphasis on
process evaluation and data to better
understand important system and
patient-level characteristics.
Appealing app features included
tracking healthy behaviors, selfmonitoring, disease education and
personalization, and customizable
content.
Interestingly, mobile-based
applications with low clinician
involvement are promising strategies
to help selected patients succeed
with improving risk factor control
and disease self-care. They may
offer a sustainable, credible, lowresource approach within the wider
technology-enabled healthcare
environment for medication
adherence at the app service level.
Supports app use for medication
adherence.
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Article 4:
Athilingam, P. et
al. (2017). A
mobile health
intervention to
improve self-care
in patients with
heart failure:
Pilot randomized
control trial.
JMIR Cardio,
1(2), e3.
Evidence LevelI
QualityTechnically, only
good quality due
to sample size,
but it is a pilot
study, so a low
sample size is
acceptable in a
pilot study
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Methods

Threats to Validity/ Reliability

Design: Randomized Control Pilot
Study
Sample: Small, only 18 participants;
9 were in control, 9 were an
intervention (all identified while in
the hospital, and outpatient home
follow-up was used to finalize
participation).
Framework: Carmen's
multidimensional framework of
patient engagement using the
information-motivation-behavioral
skills model for the conceptual
framework (asserts well informed
and motivated pts are likely to
engage in activities that enhance
knowledge and skills to obtain the
benefits of improved health.
Analysis Plan: Baseline and 30-day
evaluation points.
Procedure: The intervention group
downloaded the app on their phone
or a loaner phone and were trained
on the HeartMapp features, as well
as daily weights, symptom
assessment, responding to tailored
alerts, VS monitoring, BioHarness
strap, HF education, breathing
exercises, and walking and exercise
instructions. The app was used for 4
weeks. The control group received
only 10 educational modules
specific to HF, and the control group
accessed three modules a week. All
participants were contacted 3 times a
week the first week and 1 time a
week each week after.

Conclusion Validity: This probably
should not be thought of as being
100% applicable to the population
due to the small sample size, needs
replication in a larger sample
Internal Validity: Internal Validity
is difficult to determine given the
small sample size. Since telephone
calls were placed 3 times the first
week and once a week after, there
may have been a Hawthorne effect.
External Validity: I have decreased
confidence in the external validity of
the entire Study. There was the
improvement in medication
adherence in the intervention group.
The researchers state limited
generalizability of their findings
Construct Validity: The researchers
used the Morisky Medication
Adherence Questionnaire to assess
the potential for medication
nonadherence. It is a valid and
reliable tool; the higher the score,
the better the adherence. Lower
scores reflect nonadherence.
Reliability: I do think the Study can
be replicated but needs to use a
larger sample size
Precision: An independent t-test
was used to evaluate the two groups
at baseline and at 30 days for
medication adherence. T-tests were
used to compare time points.

Study Findings

Medication adherence improved in
the intervention group using
HeartMapp at 30 days compared to
baseline; medication adherence
worsened in the control at 30 days
compared to baseline.
Of the features on the HeartMapp,
the medication tracker and breathing
exercise features were accessed
"consistently."
Patient self-care management
increased at 30 days with a
significant p-value of .002.
Self-care management, self-care
confidence, HF knowledge all
increased with statistical
significance. Quality of life declined
in the control and intervention
groups, but more so in the control
group. This was not statistically
significant.
Only 72% of the participants
completed the 30-day follow-up,
most citing the use of the
BioHarness as the reason.

Conclusions

Researchers allowed the use of a
loaner phone if the participant did
not have one.
This app classifies users as green,
yellow, or red, depending on HF
symptoms. It notifies the patient of
the need to seek immediate attention
by the degree of symptoms and
progression.
78% engagement was noted of all
users randomized to the intervention
of the HeartMapp group, 43%
accessed it daily, five participants
(just under 33% of participants)
accessed it 80% of the time. The
least accessed feature was the BP
monitoring and the chest strap.
Participants reported the app was
easy to use but disliked the chest
strap.
Bottom line: Supports the use of
an app for medication adherence.
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Article 5: Gong,
K. et al. (2020).
Mobile health
applications for
the management
of primary
hypertension: A
multicenter,
randomized,
control trial.
Medicine 99(16),
1-5.
Evidence Level 1
Quality- Low
quality due to
improvement in
both the control
and the
intervention
groups,
confounding
findings
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Design: Multicenter Randomized
Control trial in China in 38
hospitals. Participants in the
intervention arm downloaded the
"Yan Fu" app.
Sample: There were 240 patients
enrolled in the control group and
240 patients enrolled in the
intervention group; 218 completed
the trial in the control group, 225
completed the trial in the
intervention group.
Framework: None
Analysis Plan: Evaluate findings at
baseline and 6 months
Procedure: Participants were taught
how to use the app and had
medication and BP monitoring
schedules set up. The app reminded
the participant of the dose and
timing of medicine and BP. if no
record was uploaded. BPs that were
abnormal triggered a BP recheck
message. The control group did not
use any apps, but they need to record
their BP on paper every day. All
participants were followed for 6
months.

Conclusion Validity: There was a
large sample size, but both the
control and the intervention groups
had improvement in BP, perhaps
from the effects of being in a study
alone and not the use of the app.
Internal Validity: Lack of internal
Validity from probable Hawthorne
effect
External Validity: There is a high
likelihood replicating this Study in
an Asian country would produce
similar effects, and I feel there is a
cultural component to this Study.
Construct Validity: The researchers
used the Modified Morisky Scale
(MMS-8) to assess the potential for
medication nonadherence. It is a
short, validated tool that can be used
to improve patient adherence to
treatment plans by determining
individual patient's motivations and
knowledge.
Reliability: The MMS-8 is a reliable
tool for medication
adherence/nonadherence.
Precision: There was a normal
distribution of data. T-tests were
used to evaluate the two groups.
Non-parametric testing for the
MMS-8 for medication adherence
data.

The primary outcome was directed
at the improvement in systolic and
diastolic blood pressure. There was a
statistically significant difference in
both systolic and diastolic blood
pressure in both the control and
intervention groups at the 6-month
follow-up. Still, the intervention
group had a higher reduction than
the control group with a statistical
significance of p< .05.
The medication adherence was much
higher in the intervention group than
in the control group, p <.05.

Conclusions

Since there was an improvement in
SBP and DBP in both the treatment
and control groups may be
secondary to the Hawthorne effect,
particularly within the unique
population of Chinese participants.
App had functions of personal
record, a reminder for BP,
medication administration, the
recommendation to contact
physician, ability to record BP and
medication taking, remote
consulting with physicians,
information query, emergency
contact information, relative and
doctors can monitor the participants'
records, provides 4 kinds of health
evaluations and gives personal
management advice.
Findings support the use of an app
for increasing medication
adherence.

MEDICATION APP USE READINESS IN CHF PATIENTS
Brief Reference,
Type of Study,
Quality rating

Article 6:
Johnston et al.
(2016). Effects of
interactive
patient
smartphone
support app on
drug adherence
and lifestyle
changes in
myocardial
infarction
patients: A
randomized
study. American
Heart Journal,
178, 85-94.
Evidence Level 1
Quality - Good
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Design: Multicenter, randomized
control trial
Sample: 174 ticagrelor-treated MI
patients were randomized to either
an interactive patient support tool, a
simplified tool group, or a traditional
post-MI care group. There were 91
patients in the intervention group
and 83 patients in the control group.
Framework: None
Analysis Plan: Three points:
baseline, 6 to 10 weeks, and 6
months
Procedure: Patients with a STEMI
or NSTEMI treated in-hospital with
ticagrelor 90 mg po BID and were
recruited from 16 cardiology
departments in Sweden. All patients
were evaluated at baseline, between
6 and 10 weeks after discharge, and
finally 6 months after
randomization. Patients were asked
to bring empty ticagrelor blister
packs with them for manual pill
count. The System Usability Scale
measured device usability at the 2nd
& 3rd visits.

Conclusion Validity: Supports
previous research findings, may not
be entirely generalizable
Internal Validity: Randomization
was used, but there was no blinding
External Validity: There was not a
very large sample size, so it may not
be generalizable
Construct Validity: Patients
completed the Medication
Adherence Rating Scale (MARS-5),
completed at the 2nd and 3rd visit to
determine nonadherence and type of
nonadherence. MARS-5 has high
Validity
Reliability: MARS-5 has high
reliability
Precision: Two group t-tests
assuming typical standard deviation
with a two-sided significance level,
as well as non-parametric tests for
evaluating e-diary entries. The
researchers calculated a sample size
of 74 in each group to have 80%
power to detect a difference in the
mean of 0.7 events between the two
groups, assuming that the expected
standard deviation is 1.5 using a
two-group t-test with 0.05 2-sided
significance level period to
compensate for potential dropout
during the Study. A total of 80
patients were determined necessary
to be randomized.

The mean nonadherence score was
lower in the active or intervention
group than the control group through
an analysis of the diary. The results
were 16.6 versus 22.8, with a P=
0.25.

This study supports the use of an
app for medication adherence. There
may be some Hawthorne effect with
this Study as well, given the
participants knew they were being
studied, and there was high
medication adherence in both
groups. However, the patients
randomized to the use of the
smartphone app had higher
adherence rates and improved
equally well compared with patients
participating in the usual care
regarding cardiovascular risk factor
profiles and quality of life. This
lends to the support of the use of a
smart app as there was a positive
effect and may provide secondary
prevention management in MI
patients, and perhaps CHF patients
for worsening disease process, but
the study was not powered to
measure this.

System usability score was higher in
the active or intervention group at
both the 2nd and 3rd visit. Data at the
end of the study showed a score of
87.3 versus 78.1 with P= 0.001.
The interactive patient support tool
satisfaction questionnaire showed
that 97.5% of the patients in the
intervention group at the end of the
Study would recommend the tool to
another patient in the same situation.
68.4% of patients reported
willingness to continue using the
interactive patient support tool or the
app. More than 80% of the patients
found that the app gave relevant
information about their disease and
increased their insight and
motivation to pursue a healthier
lifestyle. No adverse device events
were reported during the Study, thus
indicating no safety concerns with
the interactive patient support tool.
There were high adherence scores at
the end of the Study for both groups,
but there was a statistically
significant difference between
control and intervention medication
adherence at six months.

The researchers felt the use of the
MARS-5 was a potential weakness
in the Study, as it was a selfreporting tool and depended strictly
on memory recall by the participant.
Supports the use of smart apps for
medication adherence.

MEDICATION APP USE READINESS IN CHF PATIENTS
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Article 7: Liu et
al. (2019).
Smartphonebased selfempowerment
app on secondary
prevention of
patients with
cardiovascular
disease. Studies
in Health
Technology and
Informatics, 264,
1712-1713.
Evidence Level 1
Quality- Low
due to lack of
detail in the
publication
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Design: Two-armed randomized
control trial
Sample: 57 patients with CVD were
randomly assigned to either the use
of the HeartGuardian app (29) or the
control group (28). Inclusion criteria
were 1 hospitalization for CVD and
prescribed 1 CVD prevention drug.
There is no discussion regarding the
source of the sample.
Framework: Behavioral change
theory
Analysis Plan: 12-week
intervention
Procedure: The app has health
education features, behavioral
features with medication reminders,
and follow-up with medication
recording and daily feedback. The
primary outcome was improved
lipids through the use of the app
(LDL, total cholesterol,
triglycerides, high-density
lipoprotein). Secondary outcomes
included medication adherence and
the occurrence of major adverse
cardiac events. Primary and
secondary outcomes were measured
at baseline and the 12th week.
Participants visited the clinic the
12th week after discharge for
follow-up medication adherence was
measured by the Morisky scale.

Conclusion Validity: There is very
little information on the baseline and
post-intervention Morisky Scale
statistics.
Internal Validity: May have
Hawthorne effect
External Validity: Small sample
size in the intervention group. It may
not be fully generalizable
Construct Validity: Morisky Scale
was listed as the measurement of
medication adherence and
nonadherence, but not which
version. All versions are considered
valid and reliable.
Reliability: The Morisky Scale is
considered reliable. There is just no
published information on the
baseline and post-intervention data.
Precision: Used Chi-Square for the
difference between groups, as well
as a paired t-test

There was no significant difference
between the two groups on the
baseline data. There is no significant
difference in the baseline lipid levels
between the two groups. After 12
weeks of intervention, triglycerides
and total cholesterol were
significantly lower in the
intervention group than in the
control group, with a P equal to
0.020 and 0.014, respectively.
Baseline medication adherence was
similar between the intervention and
control groups. After the 12-week
follow-up, adherence increased
significantly in the intervention
group, 43.33% versus 82.14%, with
a P=0.002. The increase was minor
in the control group, 30% versus
37.93%, with a P=0.520. The
difference was statistically
significant, with the intervention
group exhibiting higher medication
adherence at the 12th week than the
control group, 82.14% versus
37.93% with a P=0.001. The heart
guardian app achieved a positive
effect in lowering the occurrence of
major adverse cardiac events in the
intervention group compared to the
control group at 28.75% versus
72.43% with a P= 0.001.

This 12-week smartphone-based
application intervention resulted in a
moderate improvement in lipid
levels and greater improvement in
medication adherence. These
outcomes translated into a
significant difference in the
occurrence of major adverse cardiac
events or MACE, a considerable
concern. There is the annotation that
perhaps the smart app increased the
patient's self-efficacy and provided a
form of social support. This app
features multiple integrated
interventions and customized health
education, which are a more
effective approach to achieving
behavior change than single
interventions and generic health
education. The authors do note the
Hawthorne effect may have played a
part in that the patients in the
intervention group knew they were
enrolled in a study to measure
improvements in lipid management
and medication adherence. Results
could just be the result of better
motivation in terms of a healthy
lifestyle.
Supports the use of a smart app
for increasing medication
adherence, but there is a possible
typo in the results. I may not want
to use this article as one of my
primary articles (substituted 12
months for 12 weeks).

MEDICATION APP USE READINESS IN CHF PATIENTS
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Article 8:
Mohammadi
Torkabad, S. et
al. (2020).
Effectiveness of
smartphonebased medication
reminder
application on
medication
adherence of
patients with
essential
hypertension: A
clinical trial
study. Journal of
Nursing and
Midwifery
Sciences, 7(4),
219-225.

Evidence Level 1

Quality -Good
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Design: This was a convenience
sample with assignments to
intervention and control groups. The
study participants knew they were
participating in a study; the
participants drew a colored card for
group assignment. The green cards
for the control group and red cards
for the intervention group
Sample: Participants had a
diagnosis of essential hypertension
by a cardiologist, taking at least
three anti-hypertensive medications
in the last six months before the
study, and had easy access to a
smartphone. There were 39 persons
in both the intervention and control
groups.
Framework: None
Analysis Plan: Baseline & 3 months
Procedure: the intervention group
downloaded the app "Daro Yab
2.1.0" and installed it on the
smartphone. The patient underwent
training on how to use the software
through a planned appointment in
the place of the study setting. The
patient added their medications on
the application under the supervision
of the researcher. In any case of any
problem in importing drugs, the
necessary guidance was provided by
the researcher. The app is low cost,
easy to use, keeps track of the time,
drug intervals, medication and
dosage, precautions, and type of
melody for a reminder. The control
group received routine care.

Conclusion Validity: Can be
applicable to the larger population
Internal Validity: Compromised in
randomization technique
External Validity: Can be
applicable to the general population
Construct Validity: The researchers
used the Morisky Medication
Adherence Scale (MMAS-8). This is
a valid and reliable tool. Less than 6
is considered poor medication
adherence, 6 to 8 moderate
adherence, and equal to 8 as good
adherence.
Reliability: The MMAS-8 is reliable
and valid
Precision: Based on the standard
deviation of a similar study, the
sample size was considered 39
people in each group, with a 95%
confidence, power of 90% an effect
size of three, using the formula for
comparison of means. The
appropriate non-parametric tests
were done for analysis, as well as
paired t-tests.

More than 90% of the participants
(72) had poor medication adherence
before the intervention, and all of
them had a history of drug
forgetfulness. After using the app,
all patients in the intervention group
had moderate medication adherence
findings. After the intervention
medication adherence was
significantly improved with Z =
-7637, P = 0.000. The score of the
control group did not change. Three
months after the intervention, the
medication adherence of the
interventional group was
significantly higher. The authors
recommended that improve drug
compliance was reported by the
intervention group patients over 12weeks and is attributed to
overcoming their forgetfulness
attributed to the use of the app. The
researchers report that this app was
considered a less interactive
software app and recommend that
further studies looking at a more
advanced interactive medication app
in the future.

In this study, a simple, inexpensive,
accessible application significantly
improved medication adherence in
middle-aged patients with essential
hypertension. They recommend that
health care providers include the use
of this application as part of the
patient education program. The
results of this application suggest
further use of medication apps for
improving medication knowledge
and adherence. This randomized
controlled trial from a convenience
sample supports the use of an app to
increase medication adherence.
Supports the use of smart apps for
medication adherence.

MEDICATION APP USE READINESS IN CHF PATIENTS
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Article 9:
Morawski, K. et
al. (2018).
Association of a
smartphone
application with
medication
adherence and
blood pressure
control: The
MedISAFE-BP
randomized
clinical trial.
JAMA Internal
Medicine, 178(6),
802-809.

Evidence Level 1
Quality- Poor
due to diminished
generalizability,
payment of
participants, and
participants self determining
which app was
used in the Study
despite attempted
blinding by the
researchers
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Design: Two arm randomized
clinical trial, multi-center, US.
Sample: Participants were recruited
through an online platform and
mailed a blood pressure cuff to
confirm eligibility and provide
follow-up measures. 412 people
completed the consent and had
confirmed uncontrolled
hypertension, taking 1-3 antihypertensive medications
Framework: None
Analysis Plan: Baseline, 4, 8, and
12-week follow-up occurred.
Procedure: Participants were
evaluated at baseline and 12 weeks
in self-reported medication
adherence, measured by the Morisky
Medication Adherence Scale,
measuring adherence from 0 to 8
with lower scores indicating lower
adherence, as well as changes in
systolic blood pressure. 411
participants, 209 in the intervention
group and 202 in control,
participated. Participants were 18 to
75 years old with a systolic blood
pressure 140 mmHg or higher and
had at least 1, but not more than 3,
first-line anti-hypertensive
medications in use. Anyone with a
blood pressure greater than 180 /
120 was excluded. Participants
needed to have a smartphone and
were mailed a Bluetooth BP cuff.
Participants used the Medisafe app.

Conclusion Validity: Participation
compensation may have skewed the
results, leading to difficulty with
generalizability to the population.
Internal Validity: all participants
were provided compensation of up
to $150 for their time to participate
in the Study. Several study
participants listed downloading the
Medisafe app during the course of
the trial, but the researchers never
mentioned the name of the app; this
may lead to some bias in the results
External Validity: May not be
generalizable to the population.
Construct Validity: The Morisky
Medication Adherence Scale is a
valid and reliable tool
Reliability: The MMAS is deemed a
valid and reliable tool.
Precision: The researchers sought to
enroll at least 390 patients to have
80% power to detect a 5 mmHg
difference in systolic blood pressure
between treatment arms with an
alpha of 0.5, even with a 20% loss to
follow up or standard deviation of
up to 17 millimeters of mercury. A
decrease in systolic blood pressure
of 5 millimeters of mercury
correlated clinically with meaningful
coronary heart disease and stroke
reductions. The sample size also
provided 87% power to detect a 0.5
point difference in adherence
between groups assuming a standard
deviation of 1.6, a similar loss to
follow up, and an alpha of 0.5.

Among individuals with poorly
controlled hypertension, patients
randomized to use a smartphone app
had a small improvement in selfreported medication adherence but
no change in systolic blood pressure
compared with controls. After 12
weeks, the MMAS improved by 0.4
among intervention participants and
remain unchanged among control.
After 12 weeks, the mean systolic
blood pressure decreased by 10.6
mmHg among intervention
participants and 10.1 mmHg among
controls. A limitation of the study
listed by the researchers includes
readings from home blood pressure
monitoring devices that were used to
determine trial eligibility and
evaluate outcomes rather than
approved medical cuffs. They stated
possible reductions in blood pressure
from baseline to follow-up observed
in both intervention and control
arms may have resulted from
fluctuations in these home blood
pressure devices providing the
readings. They do report that all
patients were engaged in some level
of self-monitoring over the 12-week
Study. They state that this could
have a small positive effect on blood
pressure control and medication
adherence. The researchers also list
that a change of two points in the
MMAS-8 is the minimum detectable
difference for anti-hypertensive
medication adherence, and the Study
did not meet this limit.

Overall, these researchers reported
that the Medisafe app received very
high usability scores, but they
recommended this app offer a more
disease-specific customization of
smartphone tools. Limitations
existed in this trial. Recruitment was
performed entirely online, leading to
difficulties with generalizability to
the general population, particularly
with those with poorly controlled
blood pressure.
Patients randomized to use a
smartphone app had a small
improvement in self-reported
medication adherence.
May still have clinical significance
for my project.
Supports the use of the Medisafe
app due to usability scores.

MEDICATION APP USE READINESS IN CHF PATIENTS
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Article 10: Santo
et al. (2019).
Medication
reminder
applications to
improve
adherence in
coronary heart
disease: A
randomized
clinical trial.
Heart 105(4),
323-329.
Evidence Level 1
Quality B –
High QualityAn examplar
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Design: The MEDication reminder
APPs to improve medication
adherence in Coronary Heart
Disease (medApp-CHD) Study was
a parallel design, single-center,
single-blind randomized controlled
trial. Conducted in Sydney, Australia
Sample: 136 patients with coronary
heart disease were randomized to
one of three groups; 1. usual care, 2.
a basic app, 3. an advanced app with
interactive and customizable
features. Participants were from a
convenience sample obtained by
record screening
Framework: Baseline, 3 months
Analysis Plan: The primary analysis
compared usual care versus app use
on the primary outcome of the 8 item
Morisky Medication Adherence
Scale (MMAS-8) at three months.
Procedure: 2 free medication
reminder apps were used. One basic,
the other advanced. Both were the
highest quality as identified
systematically by the researchers in
https://doi.org/10.2196/mhealth.6742
Intervention participants were
instructed and assisted in
downloading the app, inputting their
medication list, and setting daily
reminders when each medication is
taken.

Conclusion Validity: Highly
Reliable and Generalizable
Internal Validity: to minimize bias,
participants were instructed to
conceal their group allocation from
the blinded outcome assessor at the
three-month follow-up assessment
External Validity: Applicable and
generalizable
Construct Validity: The 8 item
Morisky Medication Adherence
Scale (MMAS-8) is a licensed
validated questionnaire to assess
medication adherence scores that
represent higher medication
adherence.
Reliability: MMAS-8 has high
reliability
Precision: all outcomes were
measured at baseline and three
months. A sample size of 156
participants was determined to allow
for a 20% loss to follow-up and
estimated to have a 90% power for a
two-tailed t-test at a 5% significant
level to detect an absolute difference
in medication adherence of 29%
between groups. MMAS-8 score at
three months was determined using
analysis of covariance with baseline
values of the MMAS-8 score as the
covariate. Interaction between
baseline MMAS-8 score and
treatment groups was checked, and
sensitivity analysis was done. The
categorical variables, the rate ratio
with 95% CI were estimated, and the
Chi-Square test was used to compare
outcomes between groups.

The primary outcome was available
for 152 participants, 93% of eligible
randomized participants. The
median time to follow up with 3.5
months. The mean MMAS-8 score
was significantly greater at a threemonth follow-up, representing
higher medication adherence in the
app users group than the usual care
group, being different 0.47, 95% CI,
0.12 to 0.82, P = 0.008.
There were no significant
differences in blood pressure,
cholesterol level, the mean number
of pills missed in the last seven
days, or in self-reported medication
knowledge questions between app
users and the usual care group for
secondary outcomes.
There was a significant difference
between the three groups in the
mean MAS dash 8 scores at three
months, with higher mean MMAS
dash 8 scores in the basic and
advanced app groups compared with
the usual care group.
On the feedback questionnaire, most
participants found the app useful,
easy to use, and helpful for
reminding them to take their
medications.

The MedApp-CHD Study found that
using medication reminder apps
improve medication adherence
compared with the usual care at
three-month follow-up in patients
with coronary heart disease. A
significant improvement in
medication adherence, although
numerically small, with a low cost,
simple, and scalable app
interventions could have a
significant population impact. The
researchers found no significant
differences in secondary outcome
measures. This indicates that
differences were nil or small, and a
limitation of the study is the lack of
power to detect a change in the
clinical parameters. Replication of
this study could correct this with a
larger sample size.
This is a high-level study, with the
largest number of participants found
to date. Be sure to use this Study as
a basis for the DNP project. The link
in the methods column is a direct doi
to the article with information used
by these researchers to determine
which apps to use. They definitely
used the Medisafe app.
The researchers make the
comment that health providers
prescribing the use of free
medication reminder apps could
potentially facilitate app use and
affect population health through
improved medication adherence.

MEDICATION APP USE READINESS IN CHF PATIENTS
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Article 11: Wei,
Et al. (2021).
Habits heart app
for patient
engagement in
heart failure
management:
Pilot feasibility
randomized trial.
JMIR Mhealth
and Uhealth,
9(1), e19465.
Evidence Level 1
Quality – Poor,
small sample
size, convenience
sample, pilot
study needs
replication
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Design: Randomized control pilot
study of convenience sample
performed for proof of concept.
Sample: 28 heart failure patients
enrolled, 15 in the intervention arm,
13 in the control arm.
Framework: None
Analysis Plan: Baseline and 60
days
Procedure: patients with heart
failure over the age of 18 with
smartphones were recruited from
cardiology clinics and inpatient units
at Massachusetts General Hospital.
The convenience sample was
obtained from analyzing electronic
medical records. Both HFrEF and
HFpEF were enrolled. Those in the
intervention group downloaded the
Habits Heart app on a smartphone
provided for them and had a 30minute education session. They
demonstrated competency by
performing five key actions,
including watching an education
video, logging weight on the app
using a Bluetooth link scale,
inputting sodium content entries,
inputting exercise entries, and
messaging the study team through
the app. All patients received the
standard of care for heart failure
management by cardiologists.
Patients in the control group
received written heart failure
education materials covering the
same topics as the patient education
portion of the app.

Conclusion Validity: Researcher
bias likely exists as the researchers
developed the app themselves.
Internal Validity: The app was the
only measurement of patient
participation; no outside tools were
used. Internal Validity is
compromised by the intervention
group being provided a smartphone.
This provided an incentive to
participate.
External Validity: This may not be
generalizable to the larger
population; there is likely researcher
bias as the researchers developed the
app.
Construct Validity: The researchers
briefly mention two tools used, the
Atlanta Heart Failure Knowledge
Test (AHFKT-V2), which is proven
to be valid, and the Kansas City
Cardiomyopathy Questionnaire
(KCCQ-12) abbreviated from the
original 23 question tool. This
abbreviated version is proven valid
Reliability: There is proven
reliability of the AHFKT-V2 and the
KCCQ-12
Precision: No statistical test
methods were discussed. This is a
limitation to the Study. There is a
table of demographics so that I
can evaluate these easily with the
small sample size.

Of the patients enrolled, 54% had
HFrEf, 71% were male, and the
median was 63 years. The median
follow-up was 60 days. 80% of
patients in the intervention and 85%
of the patients in the control group
completed both baseline and final
visits. In the intervention group, 2
patients were lost to follow-up, 1
patient withdrew from the Study. In
the control group, 1 patient was lost
to follow-up, and 1 patient died. 2 of
the 12 patients who completed both
study visits could not use the app
after onboarding due to intermittent
illnesses or hospitalization. Of the
10 patients who were able to use the
app, 7 patients logged >/= 1
interaction with the app QOD on
average throughout the study
duration, and 5 patients logged >/= 1
interaction with the app per day on
average throughout the Study. At the
final visit 9 out of 12 patients or
75% in the intervention group
subjectively reported regularly
interacting with the app. There was
an average of 403 screen views per
person over 56 distinct sessions. 9
reported using the app regularly,
averaging 527 screen views per
person over 73 distinct sessions. The
app triggered patient notifications
with severe symptom findings.
AHFKT-V2 scores improved
statistically from baseline to
follow-up, as did the KCCQ-12
demonstrating increased
knowledge and symptom
improvement

The researchers remarked that they
found patients with frequent
hospitalizations could not use the
app consistently; lower-risk patients
with heart failure benefited from the
habits heart app. The intervention
group appeared to have better heart
failure knowledge, quality of life,
and weight. The researchers mention
that the comprehensive interactive
tool on their app allows tracking
health habits, heart failure disease
management education, and direct
contact with staff and cardiologists
for questions regarding the app use
or medical symptoms. The
Bluetooth link scale allowed patients
to measure weight directly and
visualize trends in a centralized
setting. They listed a limitation
being the inability to link with
electronic medical records as a
current problem. They stated that
this app is a feasible way to
dynamically engage patients in heart
failure management and equip
patients with effective management
tools to potentially improve heart
failure knowledge, quality of life,
and adherence to medical
recommendations. They
recommended a larger multicenter
trial to test the app and clinical
outcomes further.
This pilot supports the use of a
smart app in heart failure
patients.

(I have the AHFKT-V2
downloaded and saved)
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Article 12:
Morrissey, et al.
(2018).
Smartphone apps
for improving
medication
adherence in
hypertension:
Patients'
perspectives.
Patient
Preference and
Adherence, 12,
813-822.
Evidence Level III
Quality-Good
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Design: Qualitative descriptive
design study based in West Ireland
Sample: 12 men and 12 women in
Ireland aged 50-83 years, mean 65
years, 75% with health insurance
Framework: Focus group
Analysis Plan: Iterative approach
Procedure: 24 patients with
hypertension were placed in focus
groups to engage in the thematic
analysis regarding smartphone apps
to improve medication adherence in
hypertension to include the
development of digital competence,
rules of engagement, and
sustainability of these technologies.
Eight focus groups were held with
24 participants. All participants
provided written informed consent
and received €20 for their
participation. Participants took at
least one anti-hypertensive
medication. Recruitment continued
until data saturation was reached and
no new themes emerged. The focus
groups were conducted at a
dedicated heart and stroke center for
the West of Ireland. The app used
was the ICP for self-management of
hypertension. It consisted of two
main aspects: a reminder to take
medication and a home blood
pressure monitoring cuff connected
via the app by Bluetooth.

Conclusion Validity: Sound theory
was used to identify the three themes
of digital competence development,
rules of engagement, and
sustainability and maintenance of
app use.
Internal Validity: NA.
External Validity: NA.
Construct Validity: NA.
Reliability: Appropriate for the type
of research
Precision: five stages of thematic
analysis, namely familiarization,
generation of codes, searching for
themes, reviewing themes, and
defining themes, were followed.
Coding was partially done by
another researcher from a different
professional background (nursing) to
the main investigator who had a
background in psychology for
intercoder reliability. To heighten
reflexivity, 4 members of the
research team, 2 health
psychologists, a general practitioner,
and a nurse joined with the lead
researcher, a Ph.D. candidate in
health psychology, to review all data
and contribute to the thematic
analysis. NVivo (version 11) was
used to organize and code the
screened transcripts to facilitate the
analysis and comparison of
relationships between the codes.

The data showed that patients could
identify the benefits of medication
reminders and recognize that selfmonitoring of their blood pressure
could be empowering in terms of
their understanding of the condition
and interactions with their general
practitioners. The data also revealed
that there are concerns about
increasing health-related anxiety and
doubts about the sustainability of
this technology over time. This
suggests that the current patient
perspective of smartphone apps
might be best characterized by
ambivalence.
Several participants were not
interested in using a smartphone app
for HTN management and had no
desire to become digitally
competent. Many felt they had
adequate systems already in place to
monitor their BP and remember to
take their medication. Others felt
using the medication reminder
function of the app would mean
they're "giving in to technology."
Some said they would be interested
in using the app in the future. Those
interested in using the app, but did
not feel comfortable operating a
smartphone, wanted instruction and
practice. Some participants valued
the app's outputs, such as graphs of
BP readings, and cited this as
motivation to become familiar with
the technology. Some wanted MD
approval for app use.

Participants in this study varied in
motivation levels, some feeling
empowered by the additional health
data the app provided, and others
expressed strong concerns about the
data, leading to increased health
anxiety. In terms of sustainability,
some concerns were raised about
using these types of apps in the long
term, but this was offset by a
confidence that the younger
generations would be very likely to
engage with them fully in the future.
Many felt using the smart app could
enhance their communication with
their general practitioners. Some
were concerned it would increase
their GP's workload but saw the app
as an opportunity to decrease the
workload as well, in that the GP
could immediately be presented with
up-to-date blood pressure data.
Focus groups were an appropriate
methodology to use for discussion
about the usability of the app as they
have high ecological validity and
facilitate the gathering of new
knowledge around issues where little
is known.
This qualitative Study recognized
many hypertensive patients are
willing and eager to engage with
smartphone apps to manage their
hypertension; it is weighed against
some concerns, particularly about
maintaining app use over time.
Supports use of smart apps
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Article 13: Park,
L. G., et al.
(2020).
Perceptions and
experiences of
using mobile
technology for
medication
adherence among
older adults with
coronary heart
disease: A
qualitative study.
Digital Health 6,
1-12.
Evidence Level III
Quality- Good
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Methods: Mixed-method study
designed to develop a 12-month
randomized clinical trial to examine
mHealth technologies to improve
medication adherence from 2
different medical centers.
Design: - Qualitative Study 3 focus
groups from a community hospital
system and another 3 from the VA
med center and each group met for 3
sessions.
Sample: 28 veteran and non-veteran
participants with a hx of CAD and
antiplatelet therapy
Framework: Grounded Theory
Analysis Plan: 3 sessions over 1
month
Procedure: Session 1: participants'
motivation for taking medications
and their opinions on the content,
frequency, and duration of text
messages, and how to overcome text
message fatigue and disinterest.
Session 2: smartphone health apps
and participant perspective on use
for medication adherence. They
were questioned about overcoming
barriers to the use of the apps for
long-term medication adherence.
They then downloaded two
medication reminder apps and
learned the apps' basic features.
They were randomly assigned to one
app use during the first week. They
were to switch to the other app the
second week after the second
session. Session 3: a review of the
use of the Medisafe and Mango
Health apps

Conclusion Validity: Strong
Internal Validity: Good
External Validity: May be
generalizable to the population
Construct Validity: Strong
principle
Reliability: Strong
Precision: all focus group and
individual sessions from both
institutions were transcribed
verbatim by a professional
transcriptionist, checked for
accuracy, and uploaded to Atlas.ti
version 7.0, a qualitative analysis
software used in grounded theory.
Grounded theory relies on the
emergence of concepts from the data
collected. Data analysis began with
inductive open coding involving the
examination of the transcripts to tag
events and common perspectives
and experiences. Data for
medication adherence itself or the
acceptability of mobile apps for
medication adherence was also
evaluated. The same qualitative
researcher who facilitated the focus
groups also coded and analyzed all
the transcripts under the supervision
of the primary investigator and coinvestigator with expertise in
qualitative research. During the
coding process, the primary
investigator and co-investigator
reviewed the emerging codes and
data tagged across the transcripts—
this ensured consistency in findings
of medication adherence and texts
related to the use of smart apps.

After analyzing the 18 focus groups
across two different health systems,
veterans and non-veterans diagnosed
with coronary heart disease can
benefit from the use of mobile apps
for medication adherence. Older
adults are engaged and can be
proficient mobile technology users.
Text messaging and mobile phone
applications are perceived as helpful
tools for medication adherence. The
researchers recommend future
research to include rigorous clinical
trials to assess mobile health
technology's efficacy in promoting
medication adherence in populations
requiring strict adherence.
Frequent themes from focus groups:
Challenges to taking medications:
Forgetfulness, busy schedule
Desired healthcare provider
feedback/interface
Suggested app feature:
accountability/family sharing and
drug interactions
Without the use of mobile
technology, participants relied on
the pillbox system for medication
adherence.
The participants verbalized concerns
over the privacy and security of
using technology.

The trial of the two apps revealed:
participants liked being able to
interact with apps and medication
reminders, medical appointment
reminders, advanced dose schedule,
prescription renewal, and refill
reminders to ensure enough
medication coverage. They liked the
availability of drug information,
interactions, side effects, health
measurement repository capability
(BP, weight, glucose, temp,
cholesterol data, charts, and graphs),
as well as adherence graphs.
The Medisafe app was graded and
used in the study by the researchers
for features to include ease of use,
high ratings from reviewers of
health apps, number of downloads,
and availability in iOS, Android, and
Windows operating systems.
Medisafe had high ratings by
participants for ease of use;
participants enjoyed getting
reminders, and participants felt it
helped them remember medications.
Save for use in the DNP project
for aspects in choosing a smart
app for project intervention.
Strong perspective on app use and
the Medisafe app ease of use.
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Article 14: Patel
et al. (2013).
Mobilizing your
medications: An
automated
medication
reminder
application for
mobile phones
and hypertension
medication
adherence in a
high-risk urban
population.
Journal of
Diabetes Science
and Technology
7(3), 630-639.
The study is
included due to
the sample being
urban DC
Medicaid
insured persons
with
hypertension
Evidence Level III
Quality- Good
as a pilot study,
but a small
sample
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Design: Convenience Pilot
Feasibility Trial
Sample: A convenience sample of
the first fifty eligible patients who
agreed to participate who had the
primary diagnosis of hypertension
were recruited from the internal
medicine, renal/hypertension, and
cardiology clinics of the George
Washington University Medical
Facility Associates. They also had
DC Medicaid as primary medical
insurance. 48 patients completed the
Study to the 7th-month visit for a
retention rate of 96%. Of the 2
participants who failed to complete
the study, 1 was admitted to a
chronic care facility, and 1 was lost
to follow-up.
Framework: None
Analysis Plan: Baseline, 1 month, 3
months, 3 months
Procedure: Participants received a
new mobile phone, at one month
after receiving the phone, they
returned for Phase 2 for unlocking
the already loaded "Pill Phone
application," a patented, FDA
cleared, secure, wireless medication
reminder software app for mobile
phones, and they were taught how to
use the app for daily use. Three
months later, in Phase 3, patients
returned, still had phone access, but
the app was disabled. A final visit
occurred 7 months after initiation of
the Study (or three months after
turning off the app).

Conclusion Validity: May not be
applicable to the general population
due to sample size, source of the
sample, and incentives for
participation.
Internal Validity: sub-population
was a convenience sample of two
particular populations, African
American patients and Medicaid
patients at a certain urban center
External Validity: Participants
were given a smartphone to use,
which may increase participation
adherence in the Study for fear of
loss of the use of the phone
Construct Validity: researchers
used the Morisky Self-Reported
Medication Scale with four
questions and the Patient Quality of
Life Questionnaire, and the Rapid
Estimate of Adult Literacy in
Medicine. All of these are valid and
reliable.
Reliability: These tools are all valid
and reliable
Precision: a power analysis
calculated using a simple two-tailed
t-test to assess differences between
the pre-intervention and intervention
time points. The power analysis
assumed 80% power with an alpha
of 0.05, estimating that a total of 44
patients would be needed to detect
the estimated intervention effect.
The data analysis was performed on
the 48 patients that completed the
Study.

Mean medication adherence was
assessed in three time periods
through ANOVA and suggested
statistically significant differences
through the three time periods with
an F=6.4 and a p=.003. Most
important was the statistically
significant difference between the
second and third phase time
points with app activation with a
p<.001.
Adherence with hypertension
medication as assessed by the
Morisky Self-Reported Medication
Scale, four questions scale at
baseline (Morisky SMS) score was
2.4, and the median score was 2. The
scale ranges from 0 to 4, with higher
scores indicating better medication
adherence. A total of 79% of the
participants scored less than 4.
Forty-six patients completed both a
baseline survey and one conducted
at the final visit. At study
completion, the mean score was 3.2,
and the median score was 3. A
paired sample t-test was used to
analyze the differences between
scores at baseline and the final study
visit. Results indicated a significant
increase in self-reported medication
adherence to hypertensive
medications between the 2 time
periods t= -5.2, P = 000

This is an uncontrolled study with a
small study population and a
relatively short study time frame.
Lack of a control group dramatically
reduces the ability to determine the
effect of the intervention. The
confounding effects of patient
education in the form of nurse
interaction throughout the Study,
literature on hypertension, and the
mobile phone itself makes
conclusions about the impact of the
Pill Phone Program more difficult.
Blood pressure declined during the
study compared to baseline.
However, this occurs in the month
after initiation and before activation
of the reminder system. The
Hawthorne effect may be at play.
The simplicity of the software
application was a strength. Still, the
researchers recommended additional
features to mobile phone-based
interventions such as prescription
refill reminders, interface with
electronic health pharmacy records,
and automated text messaging from
the pharmacy or health care team
could also improve adherence.
Early app study on a high-risk
population of lower socioeconomic
status with statistically significant
findings that a medication app
improves medication adherence.

Seminal Article
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Article 15: Sohn
et al. (2019).
Assessment of
heart failure
patients' interest
in mobile health
apps for selfcare: Survey
study. JMIR
Cardio 3(2),
e14332, 1-11.
Evidence Level III
Quality-Good
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Methods: A convenience survey
was conducted in the waiting room
in the outpatient setting
Design: Simple Survey
Sample: 50 heart failure patients in
3 outpatient follow-up settings
(internal medicine, cardiomyopathy,
and cardiology clinics) at a
university-based health system.
Persons aged 50 to 80 were eligible
and answered a self-administered
survey.
Framework: None
Analysis Plan: Single data
collection
Procedure: A 139 question survey
from a previously published,
institutional review board-approved
questionnaire was self-administered
regarding patients' interest in and
experience using technology as well
as their function, heart failure
symptoms, and heart failure selfcare. The research team asked the
participants to complete the survey
before their scheduled appointment
and informed them that it was
permitted to omit answers to any
questions. Enrolled subjects received
a gift card worth $20 (US). The
survey had 15 sections in English; a
total of four sections had questions
relating to socio-demographic
information, interests in specific
smartphone app features,
preferences regarding specific
smartphone app notifications, and
experience using technology. A 5point Likert scale was used.

Conclusion Validity: Due to the use
of tools, it may have generalizability
Internal Validity: May be biased
from selection source and provision
of gift card for participation
External Validity: High from
Validity and reliability of the tools
Construct Validity: Survey used
questions from the following tools:
Minnesota Living with Heart Failure
Questionnaire (MLHFQ), Self-Care
of Heart Failure Index (SCHFI), a
shortened version of the Seattle
Anginal Questionnaire (SAQ-7),
shorten version of the Kansas City
Cardiomyopathy Questionnaire
(KCCQ-12), Patient Reported
Outcomes Measurement Information
System (PROMIS) Global Health
and PROMIS Physical Function
short form (SF). Symptoms were
measured using a variety of
PROMIS questionnaires: Fatigue
SF, Anxiety SF, Depression SF,
Sleep Disturbance SF, and Social
Isolation SF All of these
questionnaires are valid
Reliability: All are reliable
Precision: socio-demographic data
were analyzed by descriptive
statistics. Linear regression analysis
included multivariate regression
analysis, were performed with the
participants' MLHFQ scores as the
independent variables to quantify the
linear relationships with their
interest in smartphone app features.
Alpha of .05 & 95% CI used for
statistical significance.

More than 60% (30/50) of the
survey participants expressed
interest in several potential
smartphone app features that provide
information about symptoms,
medication or treatment, activity,
and sleep. More than 25% expressed
little to no interest in documenting
their mood or receiving tips to
improve their mood. 30 participants
answered somewhat interested or
very interested in both symptomrelated statements. Of those 30
participants, 28 owned a
smartphone, and 10 owned an
activity tracker or smartwatch. Of
the 28 participants who expressed
interest (somewhat interested or very
interested) in both activity-related
statements owned a smartphone, and
11 owned an activity tracker or
smartwatch. There were 27
participants who showed interest in
both items regarding sleep periods.
Of these, 24 owned a smartphone,
and 11 owned an activity tracker or
smartwatch. Between 80 and 90% of
the participants indicated their desire
to receive reminders at least once
per day. The majority of participants
had access to technology. Participant
age correlated negatively with
interest in tracking, tips, and
reminders in multivariate regression
analysis (P<.05). In contrast,
MLHFQ scores (worse health status)
produced positive correlations with
these interests (P<.05).

This Study suggests the prospect of
heart failure patients utilizing a
smartphone app to self-monitor their
condition while also receiving tips
and reminders related to heart
failure. Access to an experience with
technology should not pose major
concerns, as 43 out of 49
participants or 88% owned a
smartphone and had access to the
Internet. MLHFQ score and age
were two factors that correlated to
the participants' degree of interest.
Scores imply that many experienced
adverse health outcomes because of
their heart failure. The statistically
significant positive correlations
between their MLHFQ score and
interest in tracking, tips, and
reminders show that heart failure
patients with lower quality of life
scores expressed greater interest in a
smartphone app for heart failure
than those with a higher quality of
life scores.
This Study indicates that heart
failure patients may be interested
in using a smart app. There is the
widespread use of existing
technology, and those with
worsening heart failure and
worsening quality of life may be
more apt to use a smart app for
medication adherence and
symptom modification.
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Appendix B
DNP Project Survey
1. Current technology use:
a.
b.
c.
d.
e.

Internet or email
Smartphone
Tablet
Tracker/Smart Watch
mHealth app(s)

Yes
Yes
Yes
Yes
Yes

No
No
No
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No
No
No

2. If mHealth app used, purpose was reported as:
a.
b.
c.
d.
e.
f.
g.
h.

To access personal medical record
To look up nutrition or diet information
To learn about health conditions
To track exercise activity or weight
To keep track of medications
To track eating habits
To record blood pressure
To record serum glucose

3. Have you missed taking any of your medications in the last seven days?
Yes

No

4. If so, what was the reason(s)?
_____________________________________________________________________
5. Interest in future use of digital and mHealth technologies:
a. Internet/smartphone for medication management
b. Internet/smartphone for medication knowledge
c. Internet/smartphone to track upcoming appointments
6. Age:
a.
b.
c.
d.
e.

18-30
31-50
51-64
65-80
80+

7. Gender:

Yes
Yes
Yes

No
No
No
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a. Male
b. Female
c. NA
8. Race:
a.
b.
c.
d.
e.

Non-Hispanic Black
Non-Hispanic White
Hispanic
Asian
Other

9. Education:
a.
b.
c.
d.
e.
f.

Less than High School
High School Diploma/Equivalency
Some College
Bachelor's Degree
Master's Degree
Post-Master's

10. Employment Status:
a.
b.
c.
d.
e.

Employed full-time
Employed part-time
Retired
Disabled
Unemployed

11. Marital Status:
a.
b.
c.
d.
e.
f.

Married
Significant other/long term partner
Single
Divorced
Widow(er)
None of the above

12. Living Situation:
a.
b.
c.
d.
e.
f.

Lives with spouse/significant other/long term partner
Lives alone
Children
Grandchildren
Friends
Assisted Living
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g. Group home
h. Extended family
i. None of the above
13. Number of times hospitalized in the last year:
a.
b.
c.
d.

Once
Twice
Three times
More than three times

14. How many days a week do you have symptoms of heart failure on average?
a.
b.
c.
d.

0
1-2
3-4
5-7

15. Number of medications prescribed before this admission:
a.
b.
c.
d.
e.
f.

0-2
2-4
4-6
7+
Can't remember
Other

16. Source of healthcare reimbursement:
a.
b.
c.
d.
e.

Private
Tricare
Medicare
Medicaid
Self-pay

17. Family income:
a.
b.
c.
d.

<$20,000
$20,000-$50,000
$50,000-$75,000
>$75,000
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Appendix C
Project Timeline and Task List
Task

Start Date

End Date

Phase 1-planning
Proposal defense
IRB application /approval
Formally introduce project
Develop consent form
Final workflow review
Develop project issue logs

11/13/2021
11/12/2021
11/13/2021
1/11/2022
11/15/2021
11/15/2021
11/15/2021

1/31/2022
11/12/2021
1/11/2022
1/31/2022
1/11/2022
1/11/2022
1/11/2022

Task Completed
Date
4/18/2022
11/12/2021
4/18/2022
4/25/2022
3/15/2022
4/18/2022
4/18/2022

Phase 2-project implementation
Pilot implementation (mock patients)
Resolve potential workflow difficulties
Begin rolling admission to project
Begin rough data analysis
Maintain project issues log

1/10/2022
1/17/2022
1/17/2022
2/1/2022
2/14/2022
1/10/2022

4/30/2022
1/31/2022
4/30/2022
4/30/2022
4/30/2022
4/30/2022

4/25/2022
4/25/2022
4/25/2022
4/25/2022
5/15/2022
6/09/2022

Phase 3-project evaluation
Develop end project PowerPoint to brief
Deliver end project PowerPoint
Analyze data
Complete project paper
Present final project defense
Meet with stakeholders for project findings
dissemination
Prepare manuscript for publication

5/1/2022
5/1/2022
5/9/2022
5/1/2022
5/1/2022
7/1/2022
7/1/2022

7/22/2022
7/7/2022
7/12/2022
6/30/2022
6/30/2022
7/22/2022
7/14/2022

7/22/2022
7/11/2022
8/11/2022
6/20/2022
7/25/2022
7/22/2022
8/11/2022

7/1/2022

7/15/2022

12/30/2022
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Appendix D
Costs And Benefits Table
Cost categories

Estimated cost and
to whom

Total

Salaries
Nurse manager

$55/HOUR (PHR)

$110

Physical materials
Paper
HP ink

$20 (student)
$40 (student)

$20
$40

Use of electronic tablets

$0

$0

Smartphone cost

$115/month (patient)
(20Something
Finance, 2021)

$115/month already
assumed by patients

Note. PHR = Prisma Health Richland

